Bart Staels

Q: What Schools Are Affiliated With Bart Staels

Bart Staels is affiliated with the following schools: University of Kentucky, University of Picardy Jules Verne, KU Leuven, Lille University of Science and Technology, University of Reading, University of Western Australia, Ghent University, University of Bergen, University of Milan, University of British Columbia, University of Edinburgh, University of Padua, University of Groningen, University of Oulu, Peking University, University of Zurich, Leiden University

Bart Staels's AcademicInfluence.com Rankings

Bart Staels

Philosophy

#2279

World Rank

#3935

Historical Rank

Logic

#513

World Rank

#942

Historical Rank

philosophy Degrees

Bart Staels

Biology

#2571

World Rank

#4054

Historical Rank

Biochemistry

#216

World Rank

#271

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Bart Staels Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Bart Staels's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (2012) (2913)
Mechanism of action of fibrates on lipid and lipoprotein metabolism. (1998) (1615)
Role of bile acids and bile acid receptors in metabolic regulation. (2009) (1386)
The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* (1997) (1292)
Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. (1996) (1237)
PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. (1996) (1215)
Transient increase in obese gene expression after food intake or insulin administration (1995) (1158)
PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. (2007) (1125)
The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. (1996) (1072)
Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators (1998) (1064)
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors (2006) (946)
Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1* (1999) (917)
Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation (2000) (917)
Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages* (1998) (866)
Protective role of interleukin-10 in atherosclerosis. (1999) (843)
PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway (2001) (833)
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. (2015) (815)
Peroxisome proliferator-activated receptors in inflammation control. (2001) (777)
Sorting out the roles of PPARα in energy metabolism and vascular homeostasis (2006) (753)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. (2016) (741)
Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients (1997) (698)
Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients (1997) (654)
Overview of Nomenclature of Nuclear Receptors (2006) (642)
Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity* (2000) (624)
Therapeutic roles of peroxisome proliferator-activated receptor agonists. (2005) (624)
Leptin (1998) (547)
Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. (1999) (535)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion (2015) (534)
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. (2004) (534)
Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. (2004) (527)
Peroxisome proliferator-activated receptors, orphans with ligands and functions. (1997) (524)
Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPARα and PPARγ Activators* (1997) (517)
The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice* (2006) (517)
Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. (2006) (505)
Improved Lipid and Lipoprotein Profile, Hepatic Insulin Sensitivity, and Glucose Tolerance in 11β-Hydroxysteroid Dehydrogenase Type 1 Null Mice* (2001) (500)
Induction of ob Gene Expression by Corticosteroids Is Accompanied by Body Weight Loss and Reduced Food Intake (*) (1995) (498)
Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. (2017) (495)
Macrophage subsets in atherosclerosis (2015) (488)
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. (2008) (473)
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. (2004) (461)
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. (1998) (456)
Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice* (1997) (456)
Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis (2008) (456)
CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. (2000) (445)
Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators* (2000) (435)
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. (2000) (435)
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. (2001) (428)
Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. (1995) (423)
Induction of the Acyl-Coenzyme A Synthetase Gene by Fibrates and Fatty Acids Is Mediated by a Peroxisome Proliferator Response Element in the C Promoter (*) (1995) (421)
Macrophage phenotypes in atherosclerosis (2014) (419)
Peroxisome Proliferator-Activated Receptor γ and Adipose Tissue—Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism (2007) (418)
Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. (1995) (417)
Estrogen-Related Receptor α Directs Peroxisome Proliferator-Activated Receptor α Signaling in the Transcriptional Control of Energy Metabolism in Cardiac and Skeletal Muscle (2004) (414)
Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis (2002) (414)
PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD (2017) (408)
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. (2006) (404)
Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. (2003) (396)
Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. (2014) (394)
Kupffer cells promote hepatic steatosis via interleukin‐1β–dependent suppression of peroxisome proliferator‐activated receptor α activity (2010) (391)
Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis (1999) (382)
Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. (1996) (370)
Dietary trans-10,cis-12 conjugated linoleic acid induces hyperinsulinemia and fatty liver in the mouse DOI 10.1194/jlr.M20008-JLR200 (2002) (368)
Peroxisome Proliferator-Activated Receptor (PPAR) &agr; and PPAR&bgr;/&dgr;, but not PPAR&ggr;, Modulate the Expression of Genes Involved in Cardiac Lipid Metabolism (2003) (353)
Human Atherosclerotic Plaque Alternative Macrophages Display Low Cholesterol Handling but High Phagocytosis Because of Distinct Activities of the PPAR&ggr; and LXR&agr; Pathways (2011) (344)
The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. (2005) (343)
Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (2013) (341)
Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy (2013) (340)
Thiazolidinediones and PPARγ agonists: time for a reassessment (2012) (334)
Expression of the Peroxisome Proliferator-activated Receptor Gene Is Stimulated by Stress and Follows a Diurnal Rhythm (*) (1996) (334)
Transcription Factor TCF7L2 Genetic Study in the French Population (2006) (327)
The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates* (1998) (325)
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. (2002) (317)
Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c* (2006) (297)
The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity. (2015) (294)
Molecular Actions of PPARα in Lipid Metabolism and Inflammation. (2018) (289)
Safety issues and prospects for future generations of PPAR modulators. (2007) (288)
Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation (2003) (287)
Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. (2005) (286)
Retinoid X receptors: common heterodimerization partners with distinct functions (2010) (281)
Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens (2009) (281)
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. (2016) (270)
Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma (2015) (267)
Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity (2011) (267)
Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. (1996) (263)
Increased ABCA1 activity protects against atherosclerosis. (2002) (262)
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients (2008) (261)
A fully dissociated compound of plant origin for inflammatory gene repression. (2005) (259)
Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators (2000) (259)
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. (2003) (258)
PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. (2006) (253)
Farnesoid X Receptor Inhibits Glucagon-Like Peptide-1 Production by Enteroendocrine L-cells (2015) (252)
Peroxisome Proliferator-Activated Receptor-α Activation as a Mechanism of Preventive Neuroprotection Induced by Chronic Fenofibrate Treatment (2003) (252)
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease (2012) (252)
Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. (1994) (251)
The role of PPARs in atherosclerosis. (2002) (249)
Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXR (2004) (248)
Peroxisome Proliferator–activated Receptors α and γ Down-regulate Allergic Inflammation and Eosinophil Activation (2003) (248)
Roles of PPARs in NAFLD: potential therapeutic targets. (2012) (245)
Glucose regulates the expression of the farnesoid X receptor in liver. (2004) (242)
Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. (1999) (238)
The orphan nuclear receptor RORα is a negative regulator of the inflammatory response (2001) (237)
Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids. (1994) (232)
Myocardial Contractile Dysfunction Is Associated With Impaired Mitochondrial Function and Dynamics in Type 2 Diabetic but Not in Obese Patients (2014) (229)
Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. (2004) (229)
PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. (2015) (226)
Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. (2007) (225)
The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition* (2005) (224)
Ela fi branor , an Agonist of the Peroxisome Proliferator L Activated Receptor L a and L d , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening (220)
The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile (2005) (220)
Peroxisome proliferator‐activated receptor γ activators affect the maturation of human monocyte‐derived dendritic cells (2001) (220)
Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor α Activators* (2003) (217)
Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation (2003) (213)
Genome-Wide Profiling of Liver X Receptor, Retinoid X Receptor, and Peroxisome Proliferator-Activated Receptor α in Mouse Liver Reveals Extensive Sharing of Binding Sites (2011) (213)
Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice (2001) (211)
ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. (2008) (210)
The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. (1996) (209)
PPAR-α–Null Mice Are Protected From High-Fat Diet–Induced Insulin Resistance (2001) (208)
Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. (2000) (208)
Distinct but complementary contributions of PPAR isotypes to energy homeostasis. (2017) (208)
Global Suppression of IL-6-induced Acute Phase Response Gene Expression after Chronic in Vivo Treatment with the Peroxisome Proliferator-activated Receptor-α Activator Fenofibrate* (2004) (207)
Bile Acid Metabolism and the Pathogenesis of Type 2 Diabetes (2011) (206)
The Orphan Nuclear Receptor Rev-Erbα Is a Peroxisome Proliferator-activated Receptor (PPAR) γ Target Gene and Promotes PPARγ-induced Adipocyte Differentiation* (2003) (206)
Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator–Activated Receptor-&agr;–Mediated Downregulation of Cholesterol 7&agr;-Hydroxylase and Sterol 27-Hydroxylase Expression (2001) (205)
A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. (2003) (205)
Regulation of Macrophage Functions by PPAR-&agr;, PPAR-&ggr;, and LXRs in Mice and Men (2008) (205)
Human ABCA1 BAC Transgenic Mice Show Increased High Density Lipoprotein Cholesterol and ApoAI-dependent Efflux Stimulated by an Internal Promoter Containing Liver X Receptor Response Elements in Intron 1* (2001) (205)
Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbα antagonism: a single-centre propensity-matched cohort study and a randomised study (2018) (201)
Regulation of steroidogenesis in NCI-H295 cells: a cellular model of the human fetal adrenal. (1993) (199)
The OSBP-related protein family in humans. (2001) (197)
FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. (2003) (197)
Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. (2005) (196)
Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor α Agonist Fenofibrate in Mice* (2002) (195)
Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. (2000) (194)
Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects (2013) (194)
Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects (2000) (194)
Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha. (2008) (193)
Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. (2006) (187)
PPARα Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages (2001) (186)
Bile Acids and Metabolic Regulation (2009) (185)
Fibrates, Glitazones, and Peroxisome Proliferator–Activated Receptors (2010) (184)
Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. (1999) (183)
Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. (2006) (183)
Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. (2002) (182)
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. (2006) (181)
The adipocyte specific transcription factor C/EBPalpha modulates human ob gene expression. (1996) (178)
The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation (2015) (178)
Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancers (2012) (178)
Macrophage polarization in metabolic disorders: functions and regulation (2011) (176)
PPARs: Transcription Factors Controlling Lipid and Lipoprotein Metabolism (2002) (176)
Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription. (2002) (174)
Peroxisome Proliferator–Activated Receptor &agr; Gene Regulates Left Ventricular Growth in Response to Exercise and Hypertension (2002) (174)
When the Clock stops ticking, metabolic syndrome explodes (2006) (171)
PPAR Tissue Distribution and Interactions with Other Hormone‐Signaling Pathways a (1996) (170)
MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. (2015) (170)
PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome (2006) (170)
Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. (2002) (169)
Severe atherosclerosis and hypoalphalipoproteinemia in the staggerer mouse, a mutant of the nuclear receptor RORalpha. (1998) (168)
Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism (2011) (168)
PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. (2007) (166)
Macrophage phenotypes and their modulation in atherosclerosis. (2014) (166)
Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. (2003) (166)
The role of fibric acids in atherosclerosis (2001) (166)
Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element. (1999) (165)
Peroxisome proliferator‐activated receptor γ activators inhibit interleukin‐12 production in murine dendritic cells (2000) (164)
PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. (2005) (164)
Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. (1999) (160)
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors (2007) (159)
Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. (1996) (158)
Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. (1997) (156)
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology (2018) (155)
Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. (1992) (153)
Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor α Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein β* (2001) (153)
A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. (1999) (153)
Fibrates and future PPARα agonists in the treatment of cardiovascular disease (2008) (153)
Oxidized phospholipids activate PPARα in a phospholipase A2‐dependent manner (2000) (152)
Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR–&agr; Activators: Clinical and Experimental Evidence (2006) (151)
LDL Receptor Knock-Out Mice Are a Physiological Model Particularly Vulnerable to Study the Onset of Inflammation in Non-Alcoholic Fatty Liver Disease (2012) (151)
Fenofibrate Simultaneously Induces Hepatic Fatty Acid Oxidation, Synthesis, and Elongation in Mice* (2009) (149)
FXR: a promising target for the metabolic syndrome? (2007) (147)
Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology (2011) (147)
Suppression of Pro-inflammatory Adhesion Molecules by PPAR-&dgr; in Human Vascular Endothelial Cells (2007) (146)
Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids. (1998) (144)
Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferator–Activated Receptor-α via Inhibition of the Protein Kinase C Signaling Pathway (2006) (143)
Survey of period variations of superhumps in SU UMa-type dwarf novae. X. The tenth year (2017) (2009) (142)
Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction (2017) (140)
Fibrates Down-regulate Hepatic Scavenger Receptor Class B Type I Protein Expression in Mice* (2003) (139)
The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response. (2001) (138)
Transcriptional Regulation of Apolipoprotein C-III Gene Expression by the Orphan Nuclear Receptor RORα* (2001) (138)
Tau deletion promotes brain insulin resistance (2017) (138)
PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. (1998) (138)
Transcriptional Regulation of Apolipoprotein A-I Gene Expression by the Nuclear Receptor RORα* (1997) (138)
Rev-erb-alpha: an integrator of circadian rhythms and metabolism. (2009) (137)
Circadian and Glucocorticoid Regulation of Rev-erbα Expression in Liver. (2000) (136)
Liver X Receptor Activation Controls Intracellular Cholesterol Trafficking and Esterification in Human Macrophages (2005) (135)
PPAR control of metabolism and cardiovascular functions (2021) (135)
Regulation of apo A-I gene expression by fibrates. (1997) (135)
Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase, and low density lipoprotein receptor in rats. (1990) (134)
Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (2014) (134)
Peroxisome Proliferator-activated Receptor α Induces Hepatic Expression of the Human Bile Acid Glucuronidating UDP-glucuronosyltransferase 2B4 Enzyme* (2003) (134)
Bile Acid Sequestrants and the Treatment of Type 2 Diabetes Mellitus (2012) (133)
Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation. (1999) (132)
Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. (2004) (131)
Circadian misalignment induces fatty acid metabolism gene profiles and compromises insulin sensitivity in human skeletal muscle (2018) (130)
Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia (2011) (128)
Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence (2010) (127)
Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression (2015) (126)
General molecular biology and architecture of nuclear receptors. (2012) (125)
Rupture of the Atherosclerotic Plaque: Does a Good Animal Model Exist? (2003) (125)
Hepatic glucose sensing is required to preserve β cell glucose competence. (2013) (124)
The UDP-glucuronosyltransferase 1A9 Enzyme Is a Peroxisome Proliferator-activated Receptor α and γ Target Gene* (2003) (124)
Peroxisome Proliferator-activated Receptor α (PPARα) Turnover by the Ubiquitin-Proteasome System Controls the Ligand-induced Expression Level of Its Target Genes* (2002) (123)
Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. (2014) (123)
Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. (1995) (122)
Peroxisome Proliferator-Activated Receptor &agr; Reduces Cholesterol Esterification in Macrophages (2003) (122)
Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator–Activated Receptor &agr; Modulation (2005) (122)
Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement. (2016) (122)
The Sirt1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression (2014) (121)
Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. (2002) (120)
The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation. (2003) (120)
Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. (2003) (119)
The two variants of oxysterol binding protein-related protein-1 display different tissue expression patterns, have different intracellular localization, and are functionally distinct. (2003) (119)
PPARS, metabolic disease and atherosclerosis. (2001) (118)
On the mechanism for PPAR agonists to enhance ABCA1 gene expression. (2009) (118)
Cardiac hypertrophy is enhanced in PPAR alpha-/- mice in response to chronic pressure overload. (2008) (117)
PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. (2001) (116)
The nuclear receptors Rev-erbs and RORs integrate circadian rhythms and metabolism (2008) (116)
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) (115)
Peroxisome Proliferator-activated Receptor-α Regulates Lipid Homeostasis, but Is Not Associated with Obesity (2001) (115)
Demonstration of a day-night rhythm in human skeletal muscle oxidative capacity (2016) (115)
PPARd, but not PPARa, activates PGC-1a gene transcription in muscle (2007) (114)
Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor (2005) (114)
Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs? (2015) (114)
Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. (1993) (112)
The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model (2017) (112)
Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice. (2017) (112)
Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice (2009) (111)
IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data (2010) (111)
DNA Binding-Independent Induction of IκBα Gene Transcription by PPARα (2002) (110)
Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. (1996) (109)
Farnesoid X Receptor Inhibits the Transcriptional Activity of Carbohydrate Response Element Binding Protein in Human Hepatocytes (2013) (109)
Mitochondrial dysfunction as an arrhythmogenic substrate: a translational proof-of-concept study in patients with metabolic syndrome in whom post-operative atrial fibrillation develops. (2013) (108)
Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. (2001) (107)
The farnesoid X receptor induces very low density lipoprotein receptor gene expression (2004) (107)
Induction of the Phospholipid Transfer Protein Gene Accounts for the High Density Lipoprotein Enlargement in Mice Treated with Fenofibrate* (2001) (107)
Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications (2003) (106)
Peroxisome Proliferator–Activated Receptor α Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets (2006) (106)
Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. (2012) (105)
Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. (2005) (105)
Dysregulated lipid metabolism links NAFLD to cardiovascular disease (2020) (105)
Liver X Receptor Activation Potentiates the Lipopolysaccharide Response in Human Macrophages (2007) (104)
Tissue-Specific Roles of ABCA1 Influence Susceptibility to Atherosclerosis (2009) (104)
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. (2020) (104)
Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. (2003) (103)
Peroxisome Proliferator-Activated Receptor γ Inhibits the Migration of Dendritic Cells: Consequences for the Immune Response1 (2003) (103)
Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes (2008) (102)
Angiotensin AT1 Receptor Antagonist Irbesartan Decreases Lesion Size, Chemokine Expression, and Macrophage Accumulation in Apolipoprotein E‐Deficient Mice (2001) (102)
The circadian clock and liver function in health and disease. (2019) (101)
Rapid and Body Weight–Independent Improvement of Endothelial and High-Density Lipoprotein Function After Roux-en-Y Gastric Bypass: Role of Glucagon-Like Peptide-1 (2015) (101)
Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis (2006) (100)
The transrepressive activity of peroxisome proliferator‐activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice (2014) (99)
Transcription of the human genes for cytochrome P450scc and P450c17 is regulated differently in human adrenal NCI-H295 cells than in mouse adrenal Y1 cells. (1997) (98)
Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis. (2009) (98)
PPARa activators improve insulin sensitivity and reduce adiposity (2000) (97)
Despite Antiatherogenic Metabolic Characteristics, SCD1-Deficient Mice Have Increased Inflammation and Atherosclerosis (2009) (97)
Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis. (2003) (97)
Nuclear bile acid signaling through the farnesoid X receptor (2015) (96)
Rev‐erbα gives a time cue to metabolism (2008) (95)
Detrimental Effects of Diet-Induced Obesity on τ Pathology Are Independent of Insulin Resistance in τ Transgenic Mice (2013) (94)
Krüppel-Like Factor KLF10 Is a Link between the Circadian Clock and Metabolism in Liver (2010) (94)
Both Hepatic and Extrahepatic ABCA1 Have Discrete and Essential Functions in the Maintenance of Plasma High-Density Lipoprotein Cholesterol Levels In Vivo (2006) (93)
Peroxisome Proliferator–Activated Receptor &agr; Induces NADPH Oxidase Activity in Macrophages, Leading to the Generation of LDL with PPAR-&agr; Activation Properties (2004) (93)
p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages. (2011) (92)
Peroxisome Proliferator–activated Receptor Activators Inhibit Oxidized Low-density Lipoprotein–induced Endothelin-1 Secretion in Endothelial Cells (2002) (92)
Intrahepatic cholesterol influences progression, inhibition and reversal of non‐alcoholic steatohepatitis in hyperlipidemic mice (2010) (92)
Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. (2003) (92)
DPP-4 inhibitors in the treatment of type 2 diabetes. (2012) (92)
PPAR&agr; Activators Inhibit Vascular Endothelial Growth Factor Receptor-2 Expression by Repressing Sp1-Dependent DNA Binding and Transactivation (2004) (91)
Human retinoic acid receptor‐related orphan receptor α1 overexpression protects neurones against oxidative stress‐induced apoptosis (2006) (91)
Transient impairment of the adaptive response to fasting in FXR‐deficient mice (2005) (90)
HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype. (2014) (89)
Effects of Pinus pinaster and Pinus koraiensis seed oil supplementation on lipoprotein metabolism in the rat (1999) (89)
The nuclear receptor FXR is expressed in pancreatic β‐cells and protects human islets from lipotoxicity (2010) (89)
Influence of development, estrogens, and food intake on apolipoprotein A-I, A-II, and E mRNA in rat liver and intestine. (1989) (89)
Statin Induction of Liver Fatty Acid-Binding Protein (L-FABP) Gene Expression Is Peroxisome Proliferator-activated Receptor-α-dependent* (2004) (88)
Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates (1997) (88)
Expression and Functional Role of Peroxisome Proliferator-Activated Receptor-γ in Ovarian Folliculogenesis in the Sheep1 (2003) (88)
Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function (2003) (88)
The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. (2016) (88)
Regulation of Macrophage Functions by Ppar (2008) (88)
Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. (2000) (87)
The Protein Kinase C Signaling Pathway Regulates a Molecular Switch between Transactivation and Transrepression Activity of the Peroxisome Proliferator-Activated Receptor α (2004) (87)
PPARα blocks glucocorticoid receptor α-mediated transactivation but cooperates with the activated glucocorticoid receptor α for transrepression on NF-κB (2009) (87)
Activation of junB by PKC and PKA signal transduction through a novel cis-acting element. (1991) (87)
SUMOylation of Human Peroxisome Proliferator-activated Receptor α Inhibits Its Trans-activity through the Recruitment of the Nuclear Corepressor NCoR* (2009) (85)
PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. (2012) (84)
Peroxisome Proliferator-activated Receptor α Is Not Rate-limiting for the Lipoprotein-lowering Action of Fish Oil* (2001) (84)
Liver X Receptor Activation Stimulates Iron Export in Human Alternative Macrophages (2013) (83)
MuscleJ: a high-content analysis method to study skeletal muscle with a new Fiji tool (2018) (82)
Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice (2010) (82)
Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation? (2012) (82)
Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway. (1998) (82)
Peroxisome proliferator‐activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages (2002) (82)
Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. (2008) (81)
Reduction of serum cholesterol by soy proteins: Clinical experience and potential molecular mechanisms (1998) (81)
Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin. (2017) (80)
Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. (2001) (80)
Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. (1997) (79)
Bile acids, farnesoid X receptor, atherosclerosis and metabolic control (2007) (78)
Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution (2019) (78)
Abundant adrenal-specific transcription of the human P450c21A "pseudogene". (1993) (77)
Innate lymphoid cells contribute to allergic airway disease exacerbation by obesity. (2016) (77)
The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). (1997) (76)
Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. (2000) (76)
Plasma bile acids are not associated with energy metabolism in humans (2010) (76)
Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. (2008) (75)
Telomerase Activation in Atherosclerosis and Induction of Telomerase Reverse Transcriptase Expression by Inflammatory Stimuli in Macrophages (2011) (75)
Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and alpha-fetoprotein as models. (1992) (75)
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. (2001) (75)
PPARs in Inflammation, Atherosclerosis and Thrombosis (2001) (75)
Human Sterol 27-Hydroxylase (CYP27) Overexpressor Transgenic Mouse Model (2002) (74)
Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support. (2018) (74)
Liver-Specific Peroxisome Proliferator–Activated Receptor α Target Gene Regulation by the Angiotensin Type 1 Receptor Blocker Telmisartan (2008) (74)
Circadian and glucocorticoid regulation of Rev-erbalpha expression in liver. (2000) (74)
Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes (2010) (74)
Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions. (2015) (73)
PPARα Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes (2007) (73)
The Farnesoid X Receptor Regulates Adipocyte Differentiation and Function by Promoting Peroxisome Proliferator-activated Receptor-γ and Interfering with the Wnt/β-Catenin Pathways* (2010) (73)
Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells. (2000) (72)
Different short- and long-term effects of resveratrol on nuclear factor-kappaB phosphorylation and nuclear appearance in human endothelial cells. (2003) (72)
Regulation of lipid and lipoprotein metabolism by retinoids. (2001) (72)
Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes (2015) (72)
PPAR&agr;, but not PPAR&ggr;, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia (2005) (71)
Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages. (2005) (71)
Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects (2017) (71)
The liver X‐receptor alpha controls hepatic expression of the human bile acid–glucuronidating UGT1A3 enzyme in human cells and transgenic mice (2006) (70)
Effect of Rosiglitazone Treatment on Plaque Inflammation and Collagen Content in Nondiabetic Patients: Data From a Randomized Placebo-Controlled Trial (2006) (70)
PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4. (2002) (70)
Age-related phenotypes in the staggerer mouse expand the RORα nuclear receptor's role beyond the cerebellum (2002) (70)
Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice Published, JLR Papers in Press, October 24, 2007. (2008) (70)
The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages. (2008) (69)
Coupled and uncoupled induction of fos and jun transcription by different second messengers in cells of hematopoietic origin. (1990) (68)
Metabolic and Innate Immune Cues Merge into a Specific Inflammatory Response via the UPR (2019) (68)
A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population (2013) (67)
The RXR Agonist Bexarotene Improves Cholesterol Homeostasis and Inhibits Atherosclerosis Progression in a Mouse Model of Mixed Dyslipidemia (2006) (67)
Human Alternative Macrophages Populate Calcified Areas of Atherosclerotic Lesions and Display Impaired RANKL-Induced Osteoclastic Bone Resorption Activity (2017) (67)
Hepatic Expression of the UGT1A9 Gene Is Governed by Hepatocyte Nuclear Factor 4α (2005) (67)
Peroxisome Proliferator-Activated Receptor (PPAR) (cid:1) and PPAR (cid:2) / (cid:3) , but not PPAR (cid:4) , Modulate the Expression of Genes Involved in Cardiac Lipid Metabolism (2003) (67)
A Mathematical Model of the Liver Circadian Clock Linking Feeding and Fasting Cycles to Clock Function. (2016) (67)
PPARγ and atherosclerosis (2005) (66)
The Natural Protective Mechanism Against Hyperglycemia in Vascular Endothelial Cells (2010) (65)
A dynamic CTCF chromatin binding landscape promotes DNA hydroxymethylation and transcriptional induction of adipocyte differentiation (2014) (65)
Peroxisome Proliferator–Activated Receptor-&agr; Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In Mice (2011) (65)
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. (2017) (65)
Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall (2001) (65)
Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice (2015) (65)
Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. (2004) (65)
Human Adipose Tissue Macrophages Display Activation of Cancer-related Pathways* (2012) (65)
IP receptor-dependent activation of PPARγ by stable prostacyclin analogues (2007) (64)
The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. (2003) (64)
Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans (2016) (64)
Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance. (2002) (64)
The PPAR&agr;/p16INK4a Pathway Inhibits Vascular Smooth Muscle Cell Proliferation by Repressing Cell Cycle–Dependent Telomerase Activation (2008) (64)
Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms. (2008) (63)
Role of Proinflammatory CD68+ Mannose Receptor− Macrophages in Peroxiredoxin-1 Expression and in Abdominal Aortic Aneurysms in Humans (2013) (63)
ATF6α downregulation of PPARα promotes lipotoxicity-induced tubulointerstitial fibrosis. (2019) (62)
Comparison of expression and regulation of the high-density lipoprotein receptor SR-BI and the low-density lipoprotein receptor in human adrenocortical carcinoma NCI-H295 cells. (1999) (62)
Bile Acid Sequestrants for Lipid and Glucose Control (2010) (62)
Does endoplasmic reticulum stress participate in APD-induced hepatic metabolic dysregulation? (2012) (62)
Role of PPAR in the Pharmacological Regulation of Lipoprotein Metabolism by Fibrates and Thiazolidinediones (1997) (61)
An Increased Flux through the Glucose 6-Phosphate Pool in Enterocytes Delays Glucose Absorption in Fxr–/– Mice* (2009) (61)
Transcriptional Regulation of Human Rev-erbα Gene Expression by the Orphan Nuclear Receptor Retinoic Acid-related Orphan Receptor α* (2002) (61)
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. (2006) (61)
PPARdelta, but not PPARalpha, activates PGC-1alpha gene transcription in muscle. (2007) (61)
Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists (2007) (61)
Apolipoprotein A-IV messenger ribonucleic acid abundance is regulated in a tissue-specific manner. (1990) (60)
Rexinoid Bexarotene Modulates Triglyceride but not Cholesterol Metabolism via Gene-Specific Permissivity of the RXR/LXR Heterodimer in the Liver (2009) (60)
Macrophage Function and Polarization in Cardiovascular Disease: A Role of Estrogen Signaling? (2013) (60)
The Farnesoid X Receptor (FXR) as Modulator of Bile Acid Metabolism (2004) (59)
Control of nuclear receptor activities in metabolism by post‐translational modifications (2011) (59)
Giardia muris Infection in Mice Is Associated with a Protective Interleukin 17A Response and Induction of Peroxisome Proliferator-Activated Receptor Alpha (2014) (59)
The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients (2006) (58)
Development, food intake, and ethinylestradiol influence hepatic triglyceride lipase and LDL-receptor mRNA levels in rats. (1990) (58)
Variable effects of different corticosteroids on plasma lipids, apolipoproteins, and hepatic apolipoprotein mRNA levels in rats. (1991) (58)
Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. (2002) (57)
Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties. (2004) (57)
Nuclear receptors linking circadian rhythms and cardiometabolic control. (2010) (56)
DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. (2002) (56)
Unlike PPARgamma, PPARalpha or PPARbeta/delta activation does not promote human monocyte differentiation toward alternative macrophages. (2009) (56)
Tissue-specific expression of the human gene for lecithin: cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile. (1995) (56)
Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells. (2008) (56)
Rev-erb alpha gives a time cue to metabolism. (2008) (55)
Transcription, adipocyte differentiation, and obesity (1996) (55)
PPARβ/δ activation induces enteroendocrine L cell GLP-1 production. (2011) (55)
The Transcriptional Regulating Protein of 132 kDa (TReP-132) Enhances P450scc Gene Transcription through Interaction with Steroidogenic Factor-1 in Human Adrenal Cells* (2002) (55)
Vascular Endothelial Damage in the Pathogenesis of Organ Injury in Severe COVID-19 (2021) (55)
The farnesoid X receptor (2004) (55)
Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor (1996) (55)
Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response. (1999) (54)
Glucose sensing O‐GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR) (2014) (54)
Metformin and pioglitazone: effectively treating insulin resistance (2006) (54)
Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humans. (2010) (53)
The Gene Encoding Acyl-CoA-binding Protein Is Subject to Metabolic Regulation by Both Sterol Regulatory Element-binding Protein and Peroxisome Proliferator-activated Receptor α in Hepatocytes* (2005) (53)
The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism (2012) (53)
11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis (2013) (53)
Hepatic de Novo Synthesis of Glucose 6-Phosphate Is Not Affected in Peroxisome Proliferator-activated Receptor α-Deficient Mice but Is Preferentially Directed toward Hepatic Glycogen Stores after a Short Term Fast* (2004) (52)
Cell-specific dysregulation of microRNA expression in obese white adipose tissue. (2014) (52)
Beneficial Metabolic Effects of Rapamycin Are Associated with Enhanced Regulatory Cells in Diet-Induced Obese Mice (2014) (52)
Transcriptional Regulation of Apolipoprotein A5 Gene Expression by the Nuclear Receptor RORα (2005) (52)
LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice. (2009) (51)
Fenofibrate, a peroxisome proliferator–activated receptor‐α agonist, exerts anticonvulsive properties (2009) (51)
Paullinia pinnata Extracts Rich in Polyphenols Promote Vascular Relaxation via Endothelium-dependent Mechanisms (2006) (51)
Peroxisome Proliferator-Activated Receptor-α Activation Protects Brain Capillary Endothelial Cells from Oxygen-Glucose Deprivation-Induced Hyperpermeability in the Blood-Brain Barrier (2009) (50)
Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response. (2008) (50)
PPARalpha regulates the production of serum Vanin‐1 by liver (2013) (50)
Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes (2016) (49)
Oncostatin M induces interleukin-6 and cyclooxygenase-2 expression in human vascular smooth muscle cells : synergy with interleukin-1beta. (1999) (49)
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity. (2005) (49)
Changes in IgG Fc receptor expression induced by phorbol 12-myristate 13-acetate treatment of THP-1 monocytic leukemia cells. (1992) (49)
Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes (2017) (48)
Combination therapy of statins and fibrates in the management of cardiovascular risk (2009) (48)
The role of the orphan nuclear receptor Rev-Erbα in adipocyte differentiation and function (2005) (48)
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. (2013) (47)
Effects of the PPAR-α Agonist Fenofibrate on Acute and Short-Term Consequences of Brain Ischemia (2014) (47)
A Review of Bile Acid Sequestrants: Potential Mechanism(s) for Glucose-Lowering Effects in Type 2 Diabetes Mellitus (2009) (47)
Peroxisome proliferator‐activated receptors – from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease (2007) (47)
Impaired alternative macrophage differentiation of peripheral blood mononuclear cells from obese subjects (2012) (47)
Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19 (2020) (47)
Oxidized phospholipids activate PPARα in a phospholipase A2-dependent manner (2000) (47)
Tissue factor pathway inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques. (2009) (46)
The nuclear orphan receptor Nur77 is a lipotoxicity sensor regulating glucose-induced insulin secretion in pancreatic β-cells. (2012) (46)
Farnesoid X receptor: a new player in glucose metabolism? (2005) (46)
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. (2017) (46)
Extracorporal albumin dialysis (MARS) improves cholestasis and normalizes low apo A-I levels in a patient with benign recurrent intrahepatic cholestasis (BRIC). (2002) (46)
The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. (2004) (46)
Schistosoma mansoni schistosomula reduce E‐selectin and VCAM‐1 expression in TNF‐α‐stimulated lung microvascular endothelial cells by interfering with the NF‐κB pathway (1999) (45)
Molecular mechanism of PPARa action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease (2015) (45)
Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization (2014) (45)
Increased Atherosclerotic Lesions in LDL Receptor Deficient Mice With Hematopoietic Nuclear Receptor Rev‐erbα Knock‐ Down (2013) (45)
4.P.263 Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl CoA synthetase (ACS) genes by PPARα and PPARγ activators (1997) (45)
Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates. (1992) (44)
Fluid retention mediated by renal PPARγ (2005) (44)
Cell Culture Conditions Determine Apolipoprotein CIII Secretion and Regulation by Fibrates in Human Hepatoma HepG2 Cells (1999) (44)
The core component of the mammalian SWI/SNF complex SMARCD3/BAF60c is a coactivator for the nuclear retinoic acid receptor (2007) (44)
PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. (2007) (44)
CX3CL1 (fractalkine) and its receptor CX3CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin (2014) (44)
[Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control]. (2002) (44)
The PPARα Activator Fenofibrate Slows Down the Progression of the Left Ventricular Dysfunction in Porcine Tachycardia-Induced Cardiomyopathy (2007) (43)
Chromatin recruitment of activated AMPK drives fasting response genes co-controlled by GR and PPARα (2016) (43)
Inhibition of progesterone production in human luteinized granulosa cells treated with LXR agonists. (2007) (43)
The farnesoid X receptor: a novel drug target? (2004) (43)
Coordinated Regulation of PPARγ Expression and Activity through Control of Chromatin Structure in Adipogenesis and Obesity (2012) (43)
PPAR alpha, fibrates, lipid metabolism and inflammation. (2004) (43)
Peroxisome proliferator-activated receptors-α and -γ, and cAMP-mediated pathways, control retinol-binding protein-4 gene expression in brown adipose tissue. (2012) (43)
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. (2005) (42)
Farnesoid X receptor represses hepatic lipase gene expression Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.M400221-JLR200 (2004) (42)
Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse Published, JLR Papers in Press, December 16, 2003. DOI 10.1194/jlr.M300432-JLR200 (2004) (42)
Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation. (1999) (42)
Hypothalamic bile acid-TGR5 signaling protects from obesity. (2021) (41)
Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPARα and PPARγ agonists (2004) (41)
Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance (2020) (41)
Hepatic PPARα is critical in the metabolic adaptation to sepsis. (2019) (41)
Transcriptional regulation of human Rev-erbalpha gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor alpha. (2002) (41)
M1 and M2 macrophage proteolytic and angiogenic profile analysis in atherosclerotic patients reveals a distinctive profile in type 2 diabetes (2015) (40)
Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants and response to fenofibrate (2013) (40)
miR-206 controls LXRα expression and promotes LXR-mediated cholesterol efflux in macrophages (2014) (40)
Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs. (1998) (39)
Characterization of New PPARγ Agonists: Analysis of Telmisartan’s Structural Components (2009) (39)
Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance. (2017) (39)
Association between liver X receptor α gene polymorphisms and risk of metabolic syndrome in French populations (2008) (39)
Schistosoma mansoni induces the synthesis of IL‐6 in pulmonary microvascular endothelial cells: role of IL‐6 in the control of lung eosinophilia during infection (2001) (39)
Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production. (2013) (39)
Dietary Sargassum fusiforme improves memory and reduces amyloid plaque load in an Alzheimer’s disease mouse model (2019) (39)
Structural and functional changes in HDL with low grade and chronic inflammation. (2015) (38)
PPAR agonists and the metabolic syndrome. (2007) (38)
Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver (2011) (38)
Retinoid-related orphan receptor gamma regulates several genes that control metabolism in skeletal muscle cells: links to modulation of reactive oxygen species production. (2007) (38)
Topical ivermectin improves allergic skin inflammation (2017) (38)
Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment (2020) (38)
The orphan nuclear receptor Rev-erbα: a transcriptional link between circadian rhythmicity and cardiometabolic disease (2007) (37)
Different ways to regulate the PPARα stability (2004) (37)
Genomic and non-genomic interactions of PPARα with xenobiotic-metabolizing enzymes (2004) (37)
Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. (2005) (37)
DHA‐derived oxylipins, neuroprostanes and protectins, differentially and dose‐dependently modulate the inflammatory response in human macrophages: Putative mechanisms through PPAR activation (2017) (37)
Skeletal muscle functions around the clock (2015) (37)
FXR‐deficiency confers increased susceptibility to torpor (2007) (37)
Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease (2006) (37)
Regulation of ob gene expression in rodents and humans. (1996) (37)
Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone—a factorial study (2014) (37)
4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation. (2008) (37)
Localization of the human OB gene (OBS) to chromosome 7q32 by fluorescence in situ hybridization. (1995) (37)
Rev-erb α : an integrator of Circadian Rhythms and Metabolism. (2009) (37)
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. (2021) (36)
Peroxisome Proliferator-activated Receptor γ Regulates Genes Involved in Insulin/Insulin-like Growth Factor Signaling and Lipid Metabolism during Adipogenesis through Functionally Distinct Enhancer Classes* (2013) (36)
Atheroprotective Effect of Human Apolipoprotein A5 in a Mouse Model of Mixed Dyslipidemia (2008) (36)
Meta-Analysis of Abdominal Aortic Aneurysm in Patients With Coronary Artery Disease. (2015) (36)
Downregulation of the tumour suppressor p16INK4A contributes to the polarisation of human macrophages toward an adipose tissue macrophage (ATM)-like phenotype (2011) (36)
Opposite regulation of hepatic lipase and lecithin: cholesterol acyltransferase by glucocorticoids in rats. (1992) (36)
IAP Survivin Regulates Atherosclerotic Macrophage Survival (2007) (35)
Intestine-specific regulation of PPARalpha gene transcription by liver X receptors. (2008) (35)
Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets (2020) (35)
Morphologic and electroretinographic phenotype of SR-BI knockout mice after a long-term atherogenic diet. (2009) (35)
Keratinocyte Expression of A20/TNFAIP3 Controls Skin Inflammation Associated with Atopic Dermatitis and Psoriasis. (2019) (35)
Liver X Receptor Activation Induces the Uptake of Cholesteryl Esters From High Density Lipoproteins in Primary Human Macrophages (2008) (34)
Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line. (2003) (34)
Neonatal extinction of liver lipoprotein lipase expression. (1992) (34)
Oxidized low-density lipoprotein and peroxisome-proliferator-activated receptor alpha down-regulate platelet-activating-factor receptor expression in human macrophages. (2001) (34)
Brinster et al. reply (2010) (34)
Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin‐dependent kinase inhibitor p27Kip1 gene (2005) (34)
Visfatin is induced by peroxisome proliferator‐activated receptor gamma in human macrophages (2010) (34)
Cdkn2a/p16Ink4a Regulates Fasting-Induced Hepatic Gluconeogenesis Through the PKA-CREB-PGC1α Pathway (2014) (34)
Down-regulation of hepatic lipase gene expression and activity by fenofibrate. (1992) (34)
SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus (2014) (34)
Peroxisome proliferator-activated receptors mediate pleiotropic actions of statins. (2007) (33)
The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis. (2018) (33)
S 26948 (2007) (33)
Lipid ligand-activated transcription factors regulating lipid storage and release in human macrophages. (2009) (33)
The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids (2020) (33)
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356 (2016) (33)
Basal transcriptional activity and cyclic adenosine 3',5'-monophosphate responsiveness of the human cytochrome P450scc promoter transfected into MA-10 Leydig cells. (1993) (33)
Rev-erb-α regulates atrophy-related genes to control skeletal muscle mass (2017) (33)
Pleiotropic effects of fibrates (2005) (32)
Inhibition of adipocyte differentiation by RORα (2009) (32)
Vasoactivity, antioxidant and aphrodisiac properties of Caesalpinia benthamiana roots. (2008) (32)
PPARgamma and atherosclerosis. (2005) (32)
Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. (2003) (32)
The glucocorticoid receptor is a co‐regulator of the orphan nuclear receptor Nurr1 (2007) (32)
Control of Gene Expression by the Retinoic Acid-Related Orphan Receptor Alpha in HepG2 Human Hepatoma Cells (2011) (32)
Alternative human liver transcripts of TCF7L2 bind to the gluconeogenesis regulator HNF4α at the protein level (2014) (32)
Combinatorial regulation of hepatic cytoplasmic signaling and nuclear transcriptional events by the OGT/REV-ERBα complex (2018) (32)
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes (2014) (31)
Retinoids Issued from Hepatic Stellate Cell Lipid Droplet Loss as Potential Signaling Molecules Orchestrating a Multicellular Liver Injury Response (2018) (31)
Metabolism of Apolipoproteins AI and AII in a Patient with Paradoxical Reduction in High-Density Lipoprotein Due to Ciprofibrate (1999) (31)
TReP-132 Controls Cell Proliferation by Regulating the Expression of the Cyclin-Dependent Kinase Inhibitors p21WAF1/Cip1 and p27Kip1 (2005) (31)
Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652 (2016) (31)
Synchronized human skeletal myotubes of lean, obese and type 2 diabetic patients maintain circadian oscillation of clock genes (2016) (31)
Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα (2019) (31)
Cardiovascular biology: A cholesterol tether (2002) (31)
Opposite in vitro and in vivo regulation of hepatic apolipoprotein A-I gene expression by retinoic acid. Absence of effects on apolipoprotein A-II gene expression. (1994) (31)
Pro-inflammatory properties for thiazolidinediones. (2005) (30)
Alternative macrophages in atherosclerosis: not always protective! (2018) (30)
The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma–associated adverse cardiac effects (2014) (30)
Coenzyme Q as an antiadipogenic factor. (2011) (30)
The RBM14/CoAA-interacting, long intergenic non-coding RNA Paral1 regulates adipogenesis and coactivates the nuclear receptor PPARγ (2017) (30)
Peroxisome Proliferator–Activated Receptor-&ggr; Activation Induces 11&bgr;-Hydroxysteroid Dehydrogenase Type 1 Activity in Human Alternative Macrophages (2012) (30)
Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell? (2019) (30)
Adipose tissue macrophages (ATM) of obese patients are releasing increased levels of prolactin during an inflammatory challenge: a role for prolactin in diabesity? (2014) (29)
Atherosclerosis: Recent trials, new targets and future directions. (2015) (29)
Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1. (2016) (29)
Bile acid sequestrants: glucose-lowering mechanisms. (2010) (29)
[Molecular mechanism of action of the fibrates]. (1999) (29)
Effects of sex steroids on hepatic and lipoprotein lipase activity and mRNA in the rat. (1993) (29)
Fenofibrate Inhibits Endothelin-1 Expression by Peroxisome Proliferator–Activated Receptor &agr;–Dependent and Independent Mechanisms in Human Endothelial Cells (2013) (29)
TReP-132 Is a Novel Progesterone Receptor Coactivator Required for the Inhibition of Breast Cancer Cell Growth and Enhancement of Differentiation by Progesterone (2006) (29)
Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK (2020) (29)
Characterization of new PPARgamma agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode. (2010) (29)
Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and LXR. (2006) (28)
Adventitial Tertiary Lymphoid Organs as Potential Source of MicroRNA Biomarkers for Abdominal Aortic Aneurysm (2015) (28)
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysis. (2014) (27)
PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH. (2011) (27)
Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings? (2009) (27)
The role of the orphan nuclear receptor Rev-Erb alpha in adipocyte differentiation and function. (2005) (27)
The neuron-derived orphan receptor 1 (NOR1) is induced upon human alternative macrophage polarization and stimulates the expression of markers of the M2 phenotype. (2015) (27)
Control of Cell Identity by the Nuclear Receptor HNF4 in Organ Pathophysiology (2020) (26)
Rôles des “Peroxisome Proliferator-Activated Receptors” (PPARs) dans la régulation du métabolisme des lipides et le contrôle de l’inflammation (2002) (26)
Transcriptional induction of rat liver apolipoprotein A-I gene expression by glucocorticoids requires the glucocorticoid receptor and a labile cell-specific protein. (1996) (26)
Plasma BCAA changes in Patients with NAFLD are Sex Dependent. (2020) (26)
PPARs: a potential target for a disease-modifying strategy in stroke. (2013) (26)
Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier. (2009) (26)
Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH) (2020) (25)
Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. (2007) (25)
O-GlcNAcylation Links ChREBP and FXR to Glucose-Sensing (2015) (25)
Intestinal bile acid receptors are key regulators of glucose homeostasis (2017) (25)
Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets (2016) (24)
Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques: evidence for a corrective effect of statins. (2007) (24)
Fenofibrate Increases Homocystinemia Through a PPAR&agr;-Mediated Mechanism (2004) (24)
Fluid retention mediated by renal PPARgamma. (2005) (24)
Hepatic sexual dimorphism — implications for non-alcoholic fatty liver disease (2021) (24)
Glycogen Dynamics Drives Lipid Droplet Biogenesis during Brown Adipocyte Differentiation (2019) (24)
Developmental extinction of liver lipoprotein lipase mRNA expression might be regulated by an NF‐1‐like site (1993) (24)
Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients (2019) (24)
Peroxisomal β-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis (2021) (24)
The hepatic orosomucoid/α1-acid glycoprotein gene cluster is regulated by the nuclear bile acid receptor FXR. (2013) (23)
Cholangiopathy and Biliary Fibrosis in Cyp2c70-Deficient Mice Are Fully Reversed by Ursodeoxycholic Acid (2020) (23)
Ketone Body Therapy Protects From Lipotoxicity and Acute Liver Failure Upon Pparα Deficiency. (2015) (23)
Structure-activity relationships of imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme. (2015) (23)
Peroxisome Proliferator-Activated Receptor (cid:1) Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery Disease (2002) (23)
Pancreatic islet response to hyperglycemia is dependent on peroxisome proliferator‐activated receptor alpha (PPARα) (2005) (23)
Liver X receptors: new players in atherogenesis? (2003) (23)
HDL does not influence the polarization of human monocytes toward an alternative phenotype. (2014) (22)
Analysis of the association of MPO and MMP-9 with stroke severity and outcome (2020) (22)
Circadian control of metabolism and pathological consequences of clock perturbations. (2017) (22)
Impaired Expression of the Inducible cAMP Early Repressor Accounts for Sustained Adipose CREB Activity in Obesity (2011) (22)
PPARβ in macrophages and atherosclerosis. (2017) (22)
Incretin combination therapy for the treatment of non‐alcoholic steatohepatitis (2020) (22)
The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release. (2019) (22)
Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat. (1996) (22)
Induction of CXCR2 Receptor by Peroxisome Proliferator-Activated Receptor &ggr; in Human Macrophages (2008) (21)
Impaired histone deacetylases 5 and 6 expression mimics the effects of obesity and hypoxia on adipocyte function (2016) (21)
Increased removal of beta-very low density lipoproteins after ethinyl estradiol is associated with increased mRNA levels for hepatic lipase, lipoprotein lipase, and the low density lipoprotein receptor in Watanabe heritable hyperlipidemic rabbits. (1991) (21)
ORP4L Facilitates Macrophage Survival via G-Protein-Coupled Signaling: ORP4L-/- Mice Display a Reduction of Atherosclerosis. (2016) (21)
The farnesoid X receptor induces fetuin-B gene expression in human hepatocytes. (2007) (21)
Expression of human apolipoprotein A‐I/C‐III/A‐IV gene cluster in mice reduces atherogenesis in response to a high fat‐high cholesterol diet (2001) (21)
Characterization of New PPARγ Agonists: Benzimidazole Derivatives – the Importance of Position 2 (2009) (21)
Hepatic trans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly[S] (2014) (21)
Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. (2018) (20)
The logic of transcriptional regulator recruitment architecture at cis-regulatory modules controlling liver functions. (2017) (20)
Short-term activation of liver X receptors inhibits osteoblasts but long-term activation does not have an impact on murine bone in vivo. (2011) (20)
Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation (2013) (20)
Control of metabolism by nutrient-regulated nuclear receptors acting in the brain (2012) (20)
Roux-en-Y gastric bypass increases systemic but not portal bile acid concentrations by decreasing hepatic bile acid uptake in minipigs (2017) (20)
Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1 Published, JLR Papers in Press, December 16, 2004. DOI 10.1194/jlr.M400400-JLR200 (2005) (20)
Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbits. (2009) (19)
Sirt6 deletion in bone marrow-derived cells increases atherosclerosis - Central role of macrophage scavenger receptor 1. (2020) (19)
Lipoprotein lipase in highly vascularized structures of the eye. (1996) (19)
Identification of Reverb as a physiological repressor of apoC-III gene transcription 1 (2002) (19)
Inhibition of cytokine production by the herbicide atrazine. Search for nuclear receptor targets. (2003) (19)
[Familial combined hyperlipidemia]. (1997) (19)
Leptin induces osteoblast differentiation of human valvular interstitial cells via the Akt and ERK pathways (2017) (18)
PPARα is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke (2014) (18)
Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARgamma agonists. (2006) (18)
SWIFT X-RAY AND ULTRAVIOLET MONITORING OF THE CLASSICAL NOVA V458 VUL (NOVA VUL 2007) (2009) (18)
PPARs in liver physiology. (2021) (18)
Lesion Progression in apoE-Deficient Mice: Implication of Chemokines and Effect of the AT1 Angiotensin II Receptor Antagonist Irbesartan (2004) (18)
Effects of Microdesmis keayana alkaloids on vascular parameters of erectile dysfunction (2009) (18)
Peroxisome proliferator-activated receptor α (PPARα)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice (2004) (18)
Pharmacological interventions in human HDL metabolism (2013) (18)
Growth hormone normalizes low-density lipoprotein receptor gene expression in hypothyroid rats. (1996) (17)
The Gene Encoding Fibrinogen-β Is a Target for Retinoic Acid Receptor-Related Orphan Receptor α (2005) (17)
FXR overexpression alters adipose tissue architecture in mice and limits its storage capacity leading to metabolic derangements[S] (2019) (16)
International observational campaigns of the last two eclipses in EE Cephei: 2003 and 2008/9 (2012) (16)
4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations. (2009) (16)
Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives. (2009) (16)
Improvement in NASH histological activity highly correlates with fibrosis regression (2016) (16)
Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonists. (2004) (16)
Studies towards the conception of new selective PPARβ/δ ligands (2006) (16)
Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. (2017) (16)
Alterations in Rev-ERBα/BMAL1 ratio and glycated hemoglobin in rotating shift workers: the EuRhythDia study (2021) (16)
Lipoprotein lipase expression in undifferentiated hepatoma cells is regulated by progesterone and protein kinase A. (1992) (16)
The Elongation Complex Components BRD4 and MLLT3/AF9 Are Transcriptional Coactivators of Nuclear Retinoid Receptors (2013) (16)
Microbiome Modulation of the Host Adaptive Immunity through Bile Acid Modification. (2020) (16)
A pan-PPAR ligand induces hepatic fatty acid oxidation in PPARalpha-/- mice possibly through PGC-1 mediated PPARdelta coactivation. (2009) (16)
Human Aortic Valve Interstitial Cells Display Proangiogenic Properties During Calcific Aortic Valve Disease (2020) (16)
Metabolic and Innate Immune Cues Merge into a Specific Inflammatory Response via the UPR (2019) (15)
The expanding role of the bile acid receptor FXR in the small intestine. (2006) (15)
The tumour suppressor CDKN2A/p16INK4a regulates adipogenesis and bone marrow-dependent development of perivascular adipose tissue (2017) (15)
Kupffer Cells Promote Hepatic Steatosis Via Interleukin-1 (cid:1) –Dependent Suppression of Peroxisome Proliferator-Activated Receptor (cid:2) Activity (2010) (15)
Bile acids contribute to the development of non-alcoholic steatohepatitis in mice (2021) (15)
The coronary artery disease‐associated gene C6ORF105 is expressed in human macrophages under the transcriptional control of PPARγ (2015) (15)
Endoplasmic reticulum stress actively suppresses hepatic molecular identity in damaged liver (2020) (15)
Near-infrared light activatable hydrogels for metformin delivery. (2019) (15)
Obesity Paradox in the Clinical Significance of Effective Prosthetic Orifice Area After Aortic Valve Replacement. (2019) (15)
Inter-subject differences in constitutive expression levels of the clock gene in man (2007) (15)
Expression and Regulation of the Lipoprotein Lipase Gene in Human Adrenal Cortex* (1996) (14)
Apolipoprotein CIII: a link between hypertriglyceridemia and vascular dysfunction? (2008) (14)
Schistosoma mansoni schistosomula reduce E-selectin and VCAM-1 expression in TNF-alpha-stimulated lung microvascular endothelial cells by interfering with the NF-kappaB pathway. (1999) (14)
From cardiac mitochondrial dysfunction to clinical arrhythmias. (2015) (14)
Electrothermal patches driving the transdermal delivery of insulin. (2020) (14)
Sox17 Regulates Liver Lipid Metabolism and Adaptation to Fasting (2014) (14)
Lack of toxic effects of F 12511, a novel potent inhibitor of acyl-coenzyme A: cholesterol O-acyltransferase, on human adrenocortical cells in culture. (2001) (14)
NASH-related increases in plasma bile acid levels depend on insulin resistance (2020) (14)
Un rôle pour PPARγ dans la reproduction (2005) (14)
Bariatric surgery, lipoprotein metabolism and cardiovascular risk (2015) (13)
Different ways to regulate the PPARalpha stability. (2004) (13)
Retinoids and nuclear retinoid receptors in white and brown adipose tissues: physiopathologic aspects (2013) (13)
Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease (2009) (13)
Macrophage function and stability of the atherosclerotic plaque: progress report of a European project. (2002) (13)
Why is elevation of serum cholesterol associated with exposure to perfluoroalkyl substances (PFAS) in humans? A workshop report on potential mechanisms (2021) (13)
Molecular Link Between Bile Acid and Lipid and Glucose Metabolism (2005) (13)
« Pharmacologie des agonistes de PPARα et PPARγ et des activateurs PPARα/γ mixtes en (2003) (13)
Failing FXR expression in the liver links aging to hepatic steatosis. (2014) (13)
How to modulate FXR activity to treat the Metabolic Syndrome (2009) (13)
Mutation screening of the PPAR agene in type 2 diabetes associated with coronary heart disease (2008) (13)
Bone Marrow p16INK4a-Deficiency Does Not Modulate Obesity, Glucose Homeostasis or Atherosclerosis Development (2012) (13)
Saturated Fatty Acids Promote GDF15 Expression in Human Macrophages through the PERK/eIF2/CHOP Signaling Pathway (2020) (13)
Ffar2 expression regulates leukaemic cell growth in vivo (2017) (13)
Complete functional rescue of the ABCA1−/− mouse by human BAC transgenesis Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.M400506-JLR200 (2005) (13)
Two regulatory elements of similar structure and placed in tandem account for the repressive activity of the first intron of the human apolipoprotein A-II gene. (1996) (13)
FXR: More than a bile acid receptor? (2006) (13)
Time to Check the Clock in Cardiovascular Research and Medicine. (2018) (13)
Soaping Up Type 2 Diabetes With Bile Acids? (2013) (13)
Obesity resistant mechanisms in the Lean polygenic mouse model as indicated by liver transcriptome and expression of selected genes in skeletal muscle (2011) (13)
Generation and characterization of a humanized PPARδ mouse model (2011) (13)
Peroxisome Proliferator – Activated Receptor-Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E 2 KnockIn Mice (2011) (12)
Inactivation of the Nuclear Orphan Receptor COUP-TFII by Small Chemicals. (2017) (12)
Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target (2021) (12)
Mitochondria and endoplasmic reticulum: Targets for a better insulin sensitivity in skeletal muscle? (2017) (12)
Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model (2019) (12)
The novel antibacterial compound walrycin A induces human PXR transcriptional activity. (2012) (12)
Effect of Oxime Ether Incorporation in Acyl Indole Derivatives on PPAR Subtype Selectivity (2012) (12)
Fenofibrate reverses the decline in HDL cholesterol in mice overexpressing human phospholipid transfer protein. (2005) (12)
Regulation of endothelial nitric oxide synthase by PPAR agonists: molecular and clinical perspectives. (2004) (12)
IPHAS J062746.41+014811.3: A DEEPLY ECLIPSING INTERMEDIATE POLAR (2012) (12)
Palmitate increases Nur77 expression by modulating ZBP89 and Sp1 binding to the Nur77 proximal promoter in pancreatic β‐cells (2013) (12)
Sex-regulated gene dosage effect of PPARα on synaptic plasticity (2019) (12)
PPARs/RXRs in Cardiovascular Physiology and Disease (2008) (12)
Transcriptional Regulation of Apolipoprotein A5 Gene Expression by theNuclear Receptor ROR alpha (2004) (12)
MPO is partially associated with neutrophil deleterious effect in acute cerebral ischemia. (2020) (12)
Deletion of fibroblast activation protein provides atheroprotection. (2020) (12)
CIDEA interacts with liver X receptors in white fat cells (2011) (11)
Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions. (2022) (11)
Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism. (2004) (11)
Endospanin-2 enhances skeletal muscle energy metabolism and running endurance capacity. (2018) (11)
Impact of Endotoxin Challenge in Obese Pigs (2014) (11)
Fibrates in CVD: a step towards personalised medicine (2010) (11)
[A role of PPARgamma in reproduction?]. (2005) (11)
Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes. (2019) (11)
Epicardial fat amount is associated with the magnitude of left ventricular remodeling in aortic stenosis (2018) (11)
Therapeutical effects of PPAR agonists assessed by biomarker modulation (2005) (11)
EUROSTERONE MEETING Peroxisome proliferator-activated receptors in inflammation control (2001) (11)
The transcriptional regulating protein of 132 kDa (TReP-132) differentially influences steroidogenic pathways in human adrenal NCI-H295 cells. (2004) (11)
FUNCTION OF THE TRANSCRIPTIONAL REGULATING PROTEIN OF 132 kDa (TReP-132) ON HUMAN P450scc GENE EXPRESSION (2002) (10)
Comment on Patel et al. ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity. Diabetes 2016;65:85–95 (2016) (10)
[4‐(2H‐1,2,3‐Benzotriazol‐2‐yl)phenoxy]alkanoic Acids as Agonists of Peroxisome Proliferator‐Activated Receptors (PPARs) (2006) (10)
Potential roles of ROR-α in cardiovascular endocrinology (2003) (10)
Retrograde cholesterol transport in the human Caco-2/TC7 cell line: a model to study trans-intestinal cholesterol excretion in atherogenic and diabetic dyslipidemia (2017) (10)
HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. (2002) (10)
Genetically-engineered animals as research models for atherosclerosis: their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders. (2007) (10)
Intestine-Liver Cross-talk in Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease. (2021) (10)
Liver X Receptor (LXR) activation negatively regulates visfatin expression in macrophages. (2011) (10)
Fasting the Microbiota to Improve Metabolism? (2017) (9)
Naturally improving insulin resistance with amorfrutins (2012) (9)
Innovative transdermal delivery of insulin using gelatin methacrylate-based microneedle patches in mice and mini-pigs. (2022) (9)
Peroxisome Proliferator-Activated Receptor β/δ: A novel target for the reduction of atherosclerosis (2005) (9)
MiR-206 controls LXR-alpha expression and promotes LXR-mediated cholesterol efflux in macrophages (2014) (9)
Peri-operative acute kidney injury upon cardiac surgery time-of-day. (2018) (9)
The gene encoding fibrinogen-beta is a target for retinoic acid receptor-related orphan receptor alpha. (2005) (9)
Peroxisome Proliferator–Activated Receptor (cid:1) Induces NADPH Oxidase Activity in Macrophages, Leading to the Generation of LDL with PPAR- (cid:1) Activation Properties (2004) (9)
Immune–metabolic interactions in homeostasis and the progression to NASH (2022) (9)
Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia and NAFLD. (2017) (9)
Risperidone-induced metabolic dysfunction is attenuated by Curcuma longa extract administration in mice (2018) (8)
Association between a thyroid hormone receptor-α gene polymorphism and blood pressure but not with coronary heart disease risk. (2011) (8)
The ubiquitous transcription factor CTCF promotes lineage-specific epigenomic remodeling and establishment of transcriptional networks driving cell differentiation (2015) (8)
SDSS J162520.29+120308.7 – a new SU Ursae Majoris star in the period gap (2011) (8)
The effects of probucol on lipoprotein metabolism in the rat. (1991) (8)
New insights into obesity genes (1996) (8)
Mechanisms Underlying the Functional Cooperation Between PPARα and GRα to Attenuate Inflammatory Responses (2019) (8)
Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis (2016) (8)
Synthesis and evaluation of new polyenic compounds as potential PPARs modulators. (2012) (8)
Altered PPARγ Expression Promotes Myelin-Induced Foam Cell Formation in Macrophages in Multiple Sclerosis (2020) (8)
Development and implementation of a cell-based assay to discover agonists of the nuclear receptor REV-ERBα (2018) (7)
Glucose transporter SGLT2 inhibition triggers glucagon secretion in alpha cells (2014) (7)
Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors (2016) (7)
[Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development]. (2003) (7)
PPAR (cid:1) Inhibits TGF- (cid:2) –Induced (cid:2) 5 Integrin Transcription in Vascular Smooth Muscle Cells by Interacting With Smad4 (2002) (7)
GIANT: galaxy-based tool for interactive analysis of transcriptomic data (2020) (7)
An oxidative stress paradox: time for a conceptual change? (2016) (7)
Efficient Gene Regulation by PPARγ and Thiazolidinediones in Skeletal Muscle and Heart (2002) (7)
Deletion of the nuclear receptor RORα in macrophages does not modify the development of obesity, insulin resistance and NASH (2020) (7)
Farnesoid X Receptor Activation in Brain Alters Brown Adipose Tissue Function via the Sympathetic System (2021) (7)
Screening strategy to generate cell specific recombination: a case report with the RIP-Cre mice (2015) (7)
The SGLT2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model (2017) (6)
Emerging small molecule drugs. (2015) (6)
Keeping an eye on circadian time in clinical research and medicine (2022) (6)
Mathematical models converge on PGC1α as the key metabolic integrator of SIRT1 and AMPK regulation of the circadian clock (2019) (6)
Cycle sequencing on large DNA templates. (1997) (6)
Rev-erbalpha2 mRNA encodes a stable protein with a potential role in circadian clock regulation. (2009) (6)
Transcription profiling in the liver of undernourished male rat offspring reveals altered lipid metabolism pathways and predisposition to hepatic steatosis. (2019) (6)
A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH (2017) (6)
Characterization of one anastomosis gastric bypass and impact of biliary and common limbs on bile acid and postprandial glucose metabolism in a minipig model. (2021) (6)
The LPS/D-Galactosamine-Induced Fulminant Hepatitis Model to Assess the Role of Ligand-Activated Nuclear Receptors on the NLRP3 Inflammasome Pathway In Vivo. (2019) (6)
Growth hormone normalizes hepatic lipase in hypothyroid rat liver. (1993) (6)
Organizing combinatorial transcription factor recruitment at cis-regulatory modules (2018) (6)
Ppar-Alpha in Lipid and Lipoprotein Metabolism, Vascular Inflammation and Atherosclerosis (2003) (6)
Light therapy improves diurnal blood pressure control in night shift workers via reduction of catecholamines: the EuRhythDia study (2021) (6)
Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression. (2017) (6)
Circumventing glucocorticoid-mediated hyperinsulinemia via the activation of PPARα (2009) (6)
The clinical significance of PPARα and γ agonism (2002) (6)
Cholesteryl‐ester transfer protein (CETP): A Kupffer cell marker linking hepatic inflammation with atherogenic dyslipidemia? (2015) (6)
Transducin‐like enhancer of split‐1 is expressed and functional in human macrophages (2016) (6)
Rôle des cofacteurs transcriptionnels dans la transduction des signaux hormonaux par les récepteurs nucléaires. (1997) (6)
Glitazones in the treatment of cardiovascular risk factors (2007) (5)
Clinical significance of electrocardiographic markers of myocardial damage prior to aortic valve replacement. (2020) (5)
Cholesterol 7&agr;-Hydroxylase Deficiency in Mice on an APOE*3-Leiden Background Increases Hepatic ABCA1 mRNA Expression and HDL-Cholesterol (2006) (5)
IFNγ-producing NK cells in adipose tissue are associated with hyperglycemia and insulin resistance in obese women (2021) (5)
Liver-Specific PPAR α-Target Gene Regulation by the Angiotensin Type 1 Receptor Blocker Telmisartan (2008) (5)
PPARα deficiency does not modify age dependency but prevents high fat diet increase in plasma PAI-1 as well as insulin resistance (2004) (5)
Nouvelles conceptions sur le mode d’action des fibrates et prospectives thérapeutiques de l’athérosclérose (2001) (5)
Horloges circadiennes et métabolisme : intégration des signaux métaboliques et environnementaux (2013) (5)
Perilipin2/adipophilin and ApoA-1 team up to combat atherosclerosis. (2016) (5)
PPARs and Atherosclerosis (2000) (5)
The hepatic compensatory response to elevated systemic sulfide promotes diabetes (2020) (5)
PPAR Inhibits TGF TGF TGF – Induced 5 Integrin Transcription in Vascular Smooth Muscle Cells by Interacting With Smad 4 (2002) (5)
The ALGOVUE Clinical Trial: Effects of the Daily Consumption of Eggs Enriched with Lutein and Docosahexaenoic Acid on Plasma Composition and Macular Pigment Optical Density (2021) (4)
Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model (2018) (4)
Induction of MDR2 P-glycoprotein (PGP) by fibrates is mediated by peroxisome proliferator-activated receptor alpha (PPARα) in the mouse (2000) (4)
Lipidomics and metabolomics signatures of SARS-CoV-2 mediators/receptors in peripheral leukocytes, jejunum and colon (2021) (4)
Nur77turing macrophages in atherosclerosis. (2012) (4)
HS 2325 + 8205—An Ideal Laboratory for Accretion Disk Physics (2012) (4)
Long-term prognostic value of preprocedural adiponectin levels in patients undergoing percutaneous coronary intervention. (2013) (4)
Effects of the NewDual PPAR a / d Agonist GFT 505 on Lipid and Glucose Homeostasis in Abdominally Obese PatientsWith Combined Dyslipidemia or Impaired GlucoseMetabolism (2011) (4)
ORP4L Facilitates Macrophage Survival via G-Protein–Coupled SignalingNovelty and Significance (2016) (4)
Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease (2020) (4)
GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice (2022) (4)
Rapid and Body Weight-Independent Improvement of Endothelial and HDL Function After Roux-enY Gastric Bypass : Role of Glucagon-Like Peptide-1 Running title : (2015) (4)
Transcriptome analysis revealed association of some P450 genes with obesity in a polygenic obese mouse model (2008) (4)
Peroxisome Proliferator-Activated Receptor γ Induces the Expression of Tissue Factor Pathway Inhibitor-1 (TFPI-1) in Human Macrophages (2016) (4)
No short‐term effect of oral isotretinoin (13‐cis retinoic acid) on lipoprotein(a) and HDL subclasses LP‐A‐I and LP‐A‐I:A‐II in healthy volunteers (1999) (4)
Circadian control of epigenetic modifications modulates metabolism. (2011) (4)
Timed physical exercise does not influence circadian rhythms and glucose tolerance in rotating night shift workers: The EuRhythDia study (2020) (4)
Measuring biomarkers to assess the therapeutic effects of PPAR agonists? (2007) (4)
Erratum: The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation (2016) (4)
The orbital and superhump periods of the dwarf nova HS 0417+7445 in Camelopardalis (2010) (4)
Les facteurs régulateurs du gène ob (1996) (4)
Hypolipidemic effects of R103757, a potent stereoselective inhibitor of microsomal triglyceride transfer protein (MTP) (1999) (4)
Response to the Letter by Finn et al (2012) (4)
CDKN2A/p16INK4a suppresses hepatic fatty acid oxidation through the AMPKα2-SIRT1-PPARα signaling pathway. (2020) (4)
Liver-specific RORα deletion does not affect the metabolic susceptibility to western style diet feeding (2019) (4)
Perspectives on the use of super-enhancers as a defining feature of cell/tissue-identity genes. (2020) (4)
Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism (2022) (4)
CDKN2A/p16INK4a suppresses hepatic fatty acid oxidation through the AMPKα2-SIRT1-PPARα signaling pathway (2020) (3)
SREBF2-embedded mir33 links the nuclear bile acid receptor FXR to cholesterol and lipoprotein metabolism. (2015) (3)
Posttranscriptional Regulation of the Human LDL Receptor by the U2-Spliceosome (2021) (3)
[PPARs activators and regulation of lipid metabolism, vascular inflammation and atherosclerosis]. (2001) (3)
Apolipoprotein A5 controls fructose-induced metabolic dysregulation in mice. (2020) (3)
Monday, 27 August 2012 (2012) (3)
Giardia muris infection in mice is associated with the intestinal activation of the Peroxisome Proliferator-Activated Receptor Alpha followed by a protective IL-17A response (2013) (3)
Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease (2012) (3)
Activation of intestinal Peroxisome Proliferator-Activated Receptor α increases HDL production (2013) (3)
The mitochondrion is the principal target for nutritional and pharmacological control of plasma triglyceride (2007) (3)
PPAR (peroxisome proliferator-activated receptors) et paroi vasculaire : implications dans l'athérosclérose. (2001) (3)
Synthesis and biological studies of "Polycerasoidol" and "trans-δ-Tocotrienolic acid" derivatives as PPARα and/or PPARγ agonists. (2021) (3)
Free leptin, carotid plaque phenotype and relevance to related symptomatology: insights from the OPAL-Lille carotid endarterectomy study. (2013) (3)
Beyond the Rule of 5: Impact of PEGylation with Various Polymer Sizes on Pharmacokinetic Properties, Structure-Properties Relationships of mPEGylated Small Agonists of TGR5 Receptor. (2021) (3)
Synthesis of benzopyran derivatives as PPARα and/or PPARγ activators. (2019) (3)
PPARα (peroxisome proliferator-activated receptor alpha) un récepteur nucléaire impliqué dans la régulation du métabolisme des lipides et des lipoprotéines ainsi que dans la réponse inflammatoire (2004) (3)
Reduced intra-adipose glucocorticoid regeneration: A novel adaptive response to, and therapy for, the metabolic syndrome (2003) (3)
PPAR activators improve glucose homeostasis by changing fatty acid partitioning (1998) (3)
Apolipoprotein A 5 , a Crucial Determinant of Plasma Triglyceride Levels , is Highly Responsive to PPAR α Activators (2003) (3)
CHAPTER 2 Reduced cholesterol absorption upon PPAR activation coincides with decreased intestinal expression of NPC 1 L 1 (2017) (3)
Author Correction: Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution (2019) (3)
Regulation of PPARα by APP in Alzheimer disease affects the pharmacological modulation of synaptic activity (2021) (3)
Drug repurposing screen identifies novel small molecule compounds with potent antifibrotic properties (2017) (3)
Intestinal ABCA1 is a significant contributor to plasma HDL-C and apoB levels in vivo (2005) (3)
PPARs in Atherosclerosis (2006) (3)
Efficient gene regulation by PPAR gamma and thiazolidinediones in skeletal muscle and heart. (2002) (3)
Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Cohort (2022) (3)
Synthesis of 2-Prenylated Alkoxylated Benzopyrans by Horner–Wadsworth–Emmons Olefination with PPARα/γ Agonist Activity (2021) (3)
Which is the eligible patient to be treated with pioglitazone? The expert view (2011) (3)
Overview of the Measurement of Lipids and Lipoproteins in Mice (2011) (3)
Rapid and Body Weight-Independent Improvement of Endothelial and HDL Function After Roux-en-Y Gastric Bypass: Role of Glucagon-Like Peptide-1 Running title: Osto et al.; Rapid effects of RYGB on endothelial and HDL function (2015) (3)
Photometry of High-Amplitude Delta Scuti Stars (2012) (3)
Palmitate increases Nur 77 expression by modulating ZBP 89 and Sp 1 binding to the Nur 77 proximal promoter in pancreatic (2013) (3)
PPARbeta in macrophages and atherosclerosis (2020) (3)
Review: Vascular protective effects of peroxisome proliferator-activated receptor agonists (2005) (2)
Etat des lieux sur la physiopathologie, le diagnostic et les traitements de la stéato-hépatite non alcoolique (NASH) (2022) (2)
New roles for PPARs in cholesterol homeostasis (2001) (2)
Regulation of macrophage lipoprotein lipase expression by activators of peroxisome proliferator-activated receptors* (1999) (2)
Functional genomics uncovers the transcription factor BNC2 as required for myofibroblastic activation in fibrosis (2022) (2)
Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption (2022) (2)
Glitazones et athérosclérose (2005) (2)
Activity and Cyclic Adenosine 3',5'-Monophosphate Responsiveness of the Human Cytochrome P45Oscc Promoter Transfected into MA- 10 Leydig Cells* (1993) (2)
1.P.194 Thiazolidinediones exert a hypotriglyceridemic effect by a distinct, but complementary mechanism relative to fibrates (1997) (2)
Hepatic de novo synthesis of glucose-6-phosphate is not affected in PPAR α-deficient mice but is preferentially directed towards hepatic glycogen stores after a short-term fast (2017) (2)
NR1D1 controls skeletal muscle calcium homeostasis through myoregulin repression (2022) (2)
22nd European Congress on Obesity (ECO2015), Prague, Czech Republic, May 6-9, 2015: Abstracts (2015) (2)
Rev-erba: a potential target for the treatment of circadian disorders (2009) (2)
Regulation of CLA-1 (CD36 and limp II analogous I) by activators of peroxisome proliferator activated receptors (PPARS) (1999) (2)
Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis (2017) (2)
Relationship between Baseline Hepatic Disease Severity and the Cardiometabolic and Anti-Inflammatory Effects of Elafibranor in Patients with Non-Alcoholic Steatohepatitis (2016) (2)
Role of bile acid receptor FXR in development and function of brown adipose tissue. (2022) (2)
Combination drug therapy allows synergistic therapeutic dose reduction in NASH: a case study of elafibranor (GFT505) and an FXR agonist combination in a model of severe NASH (2017) (2)
SDSS J162718.39+120435.0 - a dwarf nova in the period gap (2008) (2)
Palmitate increases Nur77 expression by modulating ZBP89 and Sp1 binding to the Nur77 proximal promoter in pancreatic β-cells. (2013) (2)
Diabetes mellitus and cardiovascular mortality across the spectrum of aortic stenosis (2022) (2)
FRI-355-Elafibranor, a drug candidate for first line NASH monotherapy and a universal backbone for drug combination treatment (2019) (2)
Anti-inflammatory effects and improved metabolic derangements in ob/ob mice by a newly synthesized prenylated benzopyran with pan-PPAR activity. (2022) (2)
High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation (2022) (2)
[PPAR receptors at the crossroads of obesity, diabetes and cardiovascular diseases]. (2007) (2)
PPAR gene level differently affects lipid metabolism and inflammation in apolipoprotein E 2 knockin mice (2011) (2)
A deep-learning approach for pattern recognition allows rapid and reproducible quantification of histological NASH parameters: Integration into the QuPath platform (2018) (2)
The Role of Clock Genes in Cardiometabolic Disease Reverb-: an integrator of circadian rhythms and metabolism (2009) (2)
Peroxisome Proliferator Activated Receptors: From Basic Science to Clinical Applications (2002) (2)
Summary Perturbation of developmental gene expression in rat liver by fibric acid derivatives : lipoprotein lipase and-fetoprotein as models (1999) (2)
Tissue-specific down-regulation of apo C-III gene expression by fibrates (1994) (2)
[New concepts on the mechanism of action of fibrates and therapeutic prospectives in atherosclerosis]. (2001) (2)
The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue (1997) (2)
Effect of 6-Benzoyl-benzothiazol-2-one scaffold on the pharmacological profile of α-alkoxyphenylpropionic acid derived PPAR agonists (2020) (2)
Discovery and outburst characteristics of the dwarf nova ASAS J224349+0809.5 (2010) (2)
Photometry of High-Amplitude Delta Scuti Stars in 2013 (2013) (2)
Outburst characteristics of the dwarf nova SDSS J073208.11+413008.7 (2010) (2)
Impact of light therapy on rotating night shift workers: the EuRhythDia study (2022) (2)
Increased Removal of / 8-Very Low Density Lipoproteins After Ethinyl Estradiol Is Associated With Increased mRNA Levels for Hepatic Lipase , Lipoprotein Lipase , and the Low Density Lipoprotein Receptor in Watanabe Heritable Hyperlipidemic Rabbits (2005) (1)
RORgt Inhibition in the Liver Prevents Hepatic Fibrosis Progression, a Proof of Concept Study with a Potent, First in Class, Hepatocentric RORgt Inverse Agonist (2016) (1)
5065Platelet desialylation induced by high shear-stress mechanical circulatory support (2018) (1)
MuscleJ: a high-content analysis method to study skeletal muscle with a new Fiji tool (2018) (1)
Apolipoprotein E*3-Leiden transgenic mice mode for hypolipidaemic drugs (1998) (1)
Role of the nuclear orphan receptor Rev-erb??; in the regulation of bile acid synthesis (2006) (1)
MS326 LXR ACTIVATION WITH TO901317 AND GW3965 IN MICE: DIFFERENTIAL EFFECTS ON LIVER AND INTESTINE, BUT NO NEGATIVE IMPACT ON BONE (2010) (1)
Timed use of digoxin prevents heart ischemia–reperfusion injury through a REV-ERBα–UPS signaling pathway (2022) (1)
Circadian control of epigenetic modifications modulates metabolism. Subtitle: Circadian HDAC3/NCoR recruitment to DNA regulates hepatic lipid homeostasis (2011) (1)
Nuclear transcription factors: new opportunities for lipid lowering (2000) (1)
Peroxisome proliferator-activated receptor α controls cellular cholesterol trafficking in macrophages Published, JLR Papers in Press, September 14, 2005. DOI 10.1194/jlr.M500326-JLR200 (2005) (1)
International observational campaign of the 2014 eclipse of EE Cephei (2020) (1)
Fibrates suppress bile acid synthesis via PPAR-mediated down-regulation of cholesterol 7-hydroxylase gene expression (1999) (1)
[Glitazones and atherosclerosis]. (2005) (1)
ALT as a non-invasive biomarker of histological response to pharmacotherapy in NASH patients: insights from the elafibranor GOLDEN505 trial (2016) (1)
CCD photometry of the first observed superoutburst of KP Cassiopeiae in 2008 October (2009) (1)
Peroxisome Proliferator-Activated Receptor ( PPAR ) (2003) (1)
Oral metformin transiently lowers post-prandial glucose response by reducing the apical expression of sodium-glucose co-transporter 1 in enterocytes (2023) (1)
Nuclear Receptors as Molecular Targets for Cardiometabolic and Central Nervous System Diseases (2008) (1)
Valvular interstitial cells down regulate matrix metalloproteinase 9 activity and expression in human monocyte-derived macrophages: Potential impact on aortic valve stenosis pathophysiology (2019) (1)
Tuesday, 28 August 2012 (2012) (1)
An optimized protocol with a stepwise approach to identify specific nuclear receptor ligands from cultured mammalian cells (2021) (1)
The RBM14/CoAA-interacting, long intergenic non-coding RNA Paral1 regulates adipogenesis and coactivates the nuclear receptor PPARγ (2017) (1)
The two variants of OSBP-related protein-1 ( ORP 1 ) display different tissue expression patterns , have different intracellular localization , and are functionally distinct (2002) (1)
PLPNA3 Status in Nash is Associated with Increased Histological Severity at Baseline but Not with Response to Therapy in the Golden-505 Elafibranor Trial (2016) (1)
56th EASD Annual Meeting of the European Association for the Study of Diabetes (2020) (1)
W02-P-012 The APOE2 knock-in mouse as a model for type III hyperlipidemia and steatohepatitis (2005) (1)
Differential unfolded protein response in skeletal muscle from non-diabetic glucose tolerant or intolerant patients with obesity before and after bariatric surgery (2020) (1)
Phosphorylation-dependent down-regulation of apolipoprotein A5 by insulin (2004) (1)
A central role for cholesterol metabolism and inflammation during the inhibition of non-alcoholic steatohepatitis with a synthetic PPAR alpha agonist (2008) (1)
Z Cam Stars in the Twenty-First Century (2014) (1)
Superhumps and flickering in V1316 Cygni (2007) (1)
Role of the nuclear receptor Rev-erb-alpha in the development of atherosclerosis (2015) (1)
INHIBITS ITS TRANS -ACTIVITY THROUGH THE RECRUITMENT OF THE NUCLEAR COREPRESSOR (2009) (1)
Th-W60:3 Acute anti-inflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the PKC signalling pathway (2006) (1)
cholesterol acyl t ransferase gene expression is regulated in a tissue-selective manner by fibrates (2002) (1)
European Lipoprotein Club: report of the 26th ELC Annual Conference, Tutzing, 8-11 September 2003. (2005) (1)
[The fibrate-activated PPARalpha/p16INK4A pathway inhibits vascular smooth muscle cell proliferation and vascular occlusion]. (2006) (1)
Bile acids suppress human apolipoprotein A-I gene expression via a negative response element for the nuclear receptor FXR (2001) (1)
PPAR SUMOylation: some useful experimental tips. (2013) (1)
ROLE OF PPARs IN INFLAMMATION, ATHEROSCLEROSIS, AND THROMBOSIS (2002) (1)
Abstract 19434: The Novel PPARalpha-Selective Agonist K-877 Improves Dyslipidemia, Enhances Reverse Cholesterol Transport and Decreases Inflammation and Atherosclerosis (2013) (1)
Introduction on the ATVB Review Series "Nuclear receptors in metabolism and cardiovascular disease". (2010) (1)
BEXAROTENE-ACTIVATED RXR/LXR HETERODIMER IN LIVER MODULATES TRIGLYCERIDE METABOLISM BUT NOT CHOLESTEROL HOMEOSTASIS IN VIVO (2008) (1)
The combination of elafibranor and semaglutide drastically improves fibrosing steatohepatitis and distinctly modulates liver inflammatory signature (2020) (1)
Understanding lipid metabolism through hepatic steat-omics (2019) (1)
A Post-Hoc Analysis ofthe Golden505 Trial Demonstrates Histological and Cardiometabolic Efficacy of Elafibranor-120 Mg in Patients with Moderate or Severe Nash That Are Eligible for Pharmacotherapy (2016) (1)
The hepatic compensatory response to elevated systemic sulfide impairs medium chain fat oxidation and promotes diabetes (2020) (1)
Identification of indole-based activators of insulin degrading enzyme. (2021) (1)
The outburst of V713 Cephei in 2009 August (2011) (1)
European Obesity Summit (EOS) – Joint Congress of EASO and IFSO-EC, Gothenburg, Sweden, June 1 – 4, 2016: Abstracts (2016) (1)
[Circadian rhythmicity and metabolism: integration of metabolic and environmental signals]. (2013) (1)
Nuclear Receptors in Metabolism and Cardiovascular Disease Series (2010) (1)
DCo(H2)ding the metabolic functions of SIRT1 in the intestine. (2014) (1)
Pharmacologieagonistes de PPARα et PPARγ et des activateurs PPARα/γ mixtes en développement (2003) (1)
Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation. (2023) (1)
GIANT: Galaxy-based Interactive tools for ANalysis of Transcriptomic data (2018) (1)
Photometric Observations of High-Amplitude Delta Scuti Stars (2009) (1)
W15-O-003 Atheroprotective effect of the rexinoid targretin in a murine model of atherosclerosis (2005) (1)
279-LB: NIS4, a Novel Blood Test, Can Identify "At-Risk" NASH (NAS>4 and Fibrosis>2) in T2D Patients (2019) (1)
Fibrates suppress bile acid synthesis via PPARα-mediated down-regulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase gene expression (1999) (1)
Statin induction of Liver Fatty Acid-Binding Protein (L-FABP) gene expression is PPAR aa -dependent. (2004) (1)
A New Method including the Quantification of Circulating Mirnas Allows the Efficient Identification of Nash Patients at Risk who should be Treated (2016) (1)
Rôle protecteur de la voie fibrates/p16INK4A dans les lésions vasculaires occlusives (2006) (1)
Studies towards the conception of new selective PPARbeta/delta ligands. (2006) (1)
Increase in brain superoxide dismutase as a potential mechanism of peroxisome proliferator-activated receptor alpha activator-induced brain ischemic tolerance (2000) (1)
P eroxisome Proliferator-Activated Receptors at the rossroads of Obesity , Diabetes , and Cardiovascular Disease (2006) (1)
Variation in the peroxisome proliferator activated receptor alpha gene is associated with plasma lipid concentrations, response to gemfibrozil and progression of atherosclerosis in coronary artery bypass graft patients. (1998) (0)
PPARα, Lipoprotein Metabolism, Metabolic Diseases, and Atherosclerosis (2002) (0)
Rev-erb-α regulates atrophy-related genes to control skeletal muscle mass (2017) (0)
Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients (2019) (0)
1 DPP-4 inhibitors in the treatment of type 2 diabetes (2019) (0)
Phosphorylation-dependent down-regulation of apolipoprotein A5 by 1 insulin 2 3 (2004) (0)
Nuclear receptors in metabolic control (2003) (0)
Value of Pre-Procedural Lymphocyte-to-Monocyte Ratio for Predicting New Cerebral Ischemic and Haemorrhagic Lesions Observed after Transcatheter Aortic Valve Implantation: A Pilot Study (2019) (0)
Maxima of High-Amplitude Delta Scuti Stars (2010) (0)
Topic 21 – Angiogenesis and microcirculation: April 07th, Friday 2017183 - Human aortic valvular interstitial cells: evidence of vasculogenic potential during aortic valve stenosis (2017) (0)
of the Peroxisome Proliferator-Activated Receptor-alpha Fibrates Suppress Fibrinogen Gene Expression in Rodents Via Activation (2010) (0)
Mechanisms of the hypolipidemic action of fibrates (1998) (0)
promotes IL-4-induced polarization and inhibits pro-inflammatory signaling in macrophages (2012) (0)
The nuclear receptor FXR decreases murine enteroendocrine L cell response to gut microbiota metabolites, the short chain fatty acids (2016) (0)
4.P.304 HDL (high density lipoprotein) and LDL (low density lipoprotein) receptors regulation in human adrenal cortex (1997) (0)
University of Groningen LDL Receptor Knock-Out Mice Are a Physiological Model Particularly Vulnerable to Study the Onset of Inflammation in Non-Alcoholic Fatty Liver Disease Bieghs, (2012) (0)
PPARα controlling HDL metabolism and atherosclerosis (2004) (0)
P5812Acquired von willebrand factor defect under continuous-flow ventricular assist devices: modulation by dynamic changes of pulsatility (2017) (0)
Possible role of SREBP1c in fish oil-mediated regulation of APOC-III gene expression (2000) (0)
1817-P: Elafibranor and Glucagon-Like Peptide-1 Receptor Agonists Synergize to Attenuate Hepatic Inflammation and Fibrosis in a Rodent Model of Obesity, Insulin Resistance, and NASH (2020) (0)
Hormonal Control of Genes Involved in Lipoprotein Metabolism in the Rat (1993) (0)
Nuclear receptors and regulation of inflammatory pathways (2008) (0)
A452 Differential Unfolded Protein Response expression in skeletal muscle from patients with obesity with normal or impaired glucose tolerance before and after bariatric surgery (2019) (0)
P211 Rôle pathophysiologie du récepteur nucléaire FXR dans la cellule bêta-pancréatique : connection entre l’axe entéro-hépatique et le pancréas endocrine via les acides biliaires (2014) (0)
Iconography : Mutation screening of the PPAR agene in type 2 diabetes associated with coronary heart disease (2008) (0)
Farnesoid X receptor (FXR) regulates peripheral insulin sensitivity (2005) (0)
CA-176: Effets du RYGB sur les profils d'acides biliaires systémiques : étude comparative chez le rat, le minipig et l'Homme (2016) (0)
Apolipoprotein C-III, an important player in lipoprotein metabolism (1996) (0)
Modulation of a new pathway prevent valvular interstitial cells calcification, a potential innovative therapeutic target in aortic valve stenosis (2019) (0)
Different short- and long-term effects of resveratrol on nuclear factor- (cid:2) B phosphorylation and nuclear appearance in human endothelial cells 1,2 (2003) (0)
Abstract 113: Screening of MicroRNAs Expressed in Isolated Cells of Human Abdominal Aortic Aneurysm for the Identification of Potential Biomarkers (2014) (0)
The role of BA AS signaling molecules and novel therapeutic targets to protect endothelial metabolism and function against obesity (2020) (0)
Abstract 14384: Light Therapy Improves Circadian Blood Pressure Control and Glucose Homeostasis in Rotating Night Shift Workers via Mechanisms Independent of Melatonin (2020) (0)
Culture and Adenoviral Transduction of Bone Marrow – Derived Macrophages (2007) (0)
The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism—ATVB In Focus (2005) (0)
375 Psoriasis-like inflammation in K14PPARβ/δ transgenic mice selectively overexpressing PPARβ/δ in keratinocytes (2017) (0)
Induction of acyl-coenzyme A synthetase (ACS) gene expression by fibrates is mediated by a PPAR-responsive element in the 1C promoter of the ACS gene (1994) (0)
Role of the peroxisome proliferator‐activated receptor-α in the down regulation of fibrinogen gene expression in rodents (1998) (0)
Acute Inflammation Following Dental Treatment Alters Endothelial Effects, but not Cholesterol Efflux Capacity of HDL (2012) (0)
Effects of F 12511, a potent ACAT inhibitor, on human adrenocortical cells in culture (1999) (0)
VSX J003909.7+611233: a new Slowly Pulsating B star (SPB) in Cassiopeia? (2010) (0)
PPAR-alpha activator (fenofibrate) restores endothelium responses in spontaneous hypertensive rat (2000) (0)
Expression of the PCSK9 is regulated by the nutritional statut and insulin (2006) (0)
Expression in Vascular Cells Peroxisome Proliferator-Activated Receptors and Atherogenesis : Regulators of Gene (2004) (0)
Omega-3 fatty acid-derived oxylipins reduce inflammation response in human macrophages: putative mechanism through PPAR-gamma binding (2016) (0)
Mo-W6:1 Metabolic and vascular control by lipid-sensing nuclear receptors: Role of the peroxisome proliferator-activated receptor-alpha as a mediator of the pleiotropic effects of statins (2006) (0)
Farnesoid X Receptor alters adipose tissue architecture in mice and limits storage capacity leading to metabolic derangements (2019) (0)
Multi-ring structure of the eclipsing disk in EE Cep - possible planets? (2009) (0)
A time- and space-resolved nuclear receptor atlas in mouse liver (2023) (0)
445 PPARA GENE LEVEL DIFFERENTLY AFFECTS LIPID METABOLISM AND INFLAMMATION IN APOLIPOPROTEIN E2 KNOCK-IN MICE (2011) (0)
446 ATHEROSCLEROTIC LESION REMODELLING IN REV-ERBα-DEFICIENT MICE (2011) (0)
Corresponding author: (2004) (0)
Results Iron Depots Colocalize With M 2 Macrophages in Human Atherosclerotic Plaques (0)
Alterations in bile acids and TGR5 activation in non-alcoholic steatohepatitis (2020) (0)
Abstract 19793: Pulsatility Modulates the Acquired Von Willebrand Factor Defect Related to Mechanical Circulatory Support Devices (2017) (0)
Improvement of hepatic and extrahepatic functions and anti-inflammatory effects of nitazoxanide in disease models of LPS-induced systemic inflammation and acute-on-chronic liver failure (2022) (0)
diabetes RECORD : Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes ACCORD : Action to Control Cardiovascular Risk in diabetes ACT NOW : Act Now for the Prevention of Type 2 Diabetes (2004) (0)
O53 La voie des kynurénines est dérégulée dans l’obésité (2015) (0)
O8 Rôle du gène suppresseur de tumeur CDKN2A/p16INK4a dans le développement du tissu adipeux périvasculaire (2014) (0)
CO-10: Le récepteur nucléaire FXR inhibe la sécrétion de GLP-1 en réponse aux acides gras à chaîne courte par les cellules entéroendocrines de type L (2016) (0)
Rev-erb-α : une cible thérapeutique contre la perte de masse musculaire ? (2018) (0)
O85 Les macrophages du tissu adipeux : une nouvelle cible potentielle pour les agonistes des récepteurs nucléaires LXR (Liver X Receptors) (2010) (0)
2-oxo -3,4-dihydropyridine -5-carboxylates et leur utilisation (2015) (0)
CO91 - Les souris déficientes en FXR sont résistantes à l’obésité induite par un régime riche en graisses (2008) (0)
Les peroxisome proliferator-activated receptors : des récepteurs nucléaires au carrefour entre métabolisme lipidiqueet inflammation (2001) (0)
Deprez-Poulain NatCommun 2015 6 8250 SI (2015) (0)
P196 Deux transcrits alternatifs de TCF7L2 interagissent spécifiquement avec la protéine HNF4alpha dans les cellules HepG2 (2014) (0)
Société Francophone du Diabète (SFD): Communications Affichées Et DiscutéesCAD-29 - Rôle du récepteur nucléaire Farnésoid X (FXR) dans la réponse hypothalamique à l’insuline (2017) (0)
P222 Expression différentielle de transcrits alternatifs de TCF7L2 dans le foie humain diabétique, et leur induction par l’insuline dans les cellules hépatiques HepG2. (2012) (0)
dans les lésions vasculaires occlusives (2006) (0)
O54 Le récepteur nucléaire FXR régule la fonction β-pancréatique en conditions de lipotoxicité (2010) (0)
Psoriasis et syndrome métabolique: un lien physiopathologique ? (2014) (0)
Perturbation de la signalisation endocrinienne du récepteur aux acides biliaires FXR par l’AMPK (2014) (0)
O78 Le GFT505, premier co-agoniste PPAR α/δ, a une double action favorable sur les paramètres lipidiques et glucidiques chez les sujets pré-diabétiques (2011) (0)
Rôle des PPARs dans la régulation du métabolisme des lipoprotéines et de l'athérosclérose (2001) (0)
CO57 - OB-RGRP, une protéine qui réduit la sensibilité à l’hormone de croissance en modulant l’expression du récepteur à l’hormone de croissance à la membrane plasmique (2008) (0)
Superoutbursts of the SU UMa-type dwarf nova CP Draconis (2010) (0)
A004 L’hyperméthylation du gène du tissue factor pathway inhibitor-2 est associée à une diminution de son expression dans la plaque d’athérosclérose carotidienne (2009) (0)
O37 Le récepteur nucléaire FXR régule la fonction et la différenciation adipocytaire en interférant avec la voie Wnt/β-caténine et en induisant la voie de signalisation de PPARγ (2010) (0)
O23 Cdkn2a/p16Ink4a régule la néoglucogenèse hépatique via la voie PKA-CREB-PGC1A (2014) (0)
La mutation staggerer du récepteur nucléaire RORα, ou comment un phénotype peut en cacher un autre. (1999) (0)
Modulating liver inflammation: a crucial role for cholesterol (2008) (0)
Transcription, différenciation adipocytaire et obésité (1996) (0)
O45 Le GFT505, un co-agoniste PPARα/δ, améliore la sensibilité périphérique et hépatique à l’insuline chez des patients obèses insulinorésistants (2013) (0)
P150 Stratégie de génotypage pour détecter les recombinaisons non-spécifiques dans le système Cre-Lox: exemples des souches RIP-CRE et aP2-CRE (2015) (0)
Surexpression kératinocytaire de PPARß/δ chez la souris : un modèle de psoriasis ? (2016) (0)
Chronobiologie et implications en pathologie cardiovasculaire (2022) (0)
O21 Le récepteur nucléaire FXR diminue la capacité des cellules L entéroendocrines à répondre au glucose (2015) (0)
P1051 Analyse des transcrits alternatifs de TCF7L2 et de leur implication dans la régulation de la néoglucogénèse dans le foie (2013) (0)
PO32 L’activation du récepteur nucléaire FXR module la capacité des cellules L entéroendocrines à sécréter GLP-1 (2014) (0)
Rôle de CDKN2A/p16Ink4a, un gène suppresseur de tumeur, dans le contrôle du métabolisme hépatique des lipides : impact dans le développement des NAFLD (2017) (0)
Adiponutrin, a lipid droplet surface enzyme - evidence for regulation by ChREBP, SREBP1c and FXR in human hepatocytes (2010) (0)
EMBO workshop on immunology and metabolism (2011) (0)
Modification du pool des acides biliaires le long du tractus intestinal par la chirurgie bariatrique (2018) (0)
W15-IS-002 Role of farnesoid X receptor (FXR) in control of plasma lipid levels (2005) (0)
Abstract 15299: Role of Leptin on Plaque Stability: Insights From the Opal (OPtimized management of Atherosclerosis in various Localizations) Carotid Endarterectomy Study (2011) (0)
VascularSMCproliferationisacrucialeventinocclusivecardiovasculardiseases.PPARαisanuclearrecep- torcontrollinglipidmetabolismandinflammation,butitsroleintheregulationofSMCgrowthremains tobeestablished.Here,weshowthatPPARα controlsSMCcell-cycleprogressionattheG 1 /Stransitionby (2005) (0)
Growth hormone normalizes LDL-receptor quantity, but not LDL clearance in hypothyroid rats (1994) (0)
Hormonal regulation of the genes involved in lipoprotein metabolism in the rat [Contrôle hormonal des gènes impliqués dans le métabolisme lipoprotéique chez le rat] (1995) (0)
2.P.139 Effects of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses lpA-I and lpA-I: A-II in healthy volunteers (1997) (0)
Diminution de l’Extraction Hépatique de l’Insuline Postprandiale après Chirurgie de Gastric Bypass (2017) (0)
1409 THE NEW DUAL PPARα/δ AGONIST GFT505 IMPROVES HEPATIC INSULIN RESISTANCE AND DECREASES SERUM LIVER ENZYMES IN ABDOMINALLY OBESE PATIENTS (2012) (0)
Postoperative atrial fibrillation following cardiac surgery is associated with pre-existing inflammatory dysregulation in epicardial adipose tissue. Insights from transcriptomic analysis (2019) (0)
Serum levels of miR-34a to rule-out NAFLD in healthy subjects and identify NAFLD patients with active NASH (NAS>= 4) and significant liver fibrosis (F >= 2) (2020) (0)
patients The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic (2011) (0)
ペルオキシソーム増殖因子活性化受容体γはヒトマクロファージにおける組織因子経路阻害因子‐1(TFPI‐1)の発現を誘導する (2016) (0)
Abstract 261: Dissociation of Anti-inflammatory from Normolipemic Properties of PPARalpha (2006) (0)
Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution (2019) (0)
Subject Index, Vol. 40, 1993 (1993) (0)
Author response for "Incretin combination therapy for the treatment of non-alcoholic steatohepatitis" (2020) (0)
Systemic Delivery of Murine IL-10 by Intramuscular Injection of Expression Plasmid (1999) (0)
Characterization of Individuals With Bile Acid Malabsorption (2022) (0)
DPP9 as a Potential Novel Mediator in Gastrointestinal Virus Infection (2022) (0)
A method for identifying substances for treatment of inflammation due to consumption by the ROR response element of IkappaBalpha gens (2001) (0)
Abstract 19426: Circulating Sirt1 Protects Against Atherosclerosis Through Its Modulation of Pcsk9 Activity (2016) (0)
Extensive mapping of PPAR binding to genomic DNA (2008) (0)
W15-P-005 Regulation of genes encoding intestinal cholesterol transporters by nuclear receptors in human CACO-2/TC7 enterocytes (2005) (0)
Peroxisome proliferator-activated receptors: good and bad (2008) (0)
SREBF 2-Embedded mir 33 Links the Nuclear Bile Acid Receptor FXR to Cholesterol and Lipoprotein Metabolism (2015) (0)
Macrophage-specific inactivation of the nuclear receptor ROR-alpha leads to increased atherosclerosis in mouse (2014) (0)
Structure and promoter analysis of the human PPARa gene (2000) (0)
Time-of-day-dependent variation of the hepatic transcriptome and metabolome is disrupted in non-alcoholic fatty liver disease patients (2023) (0)
Mimicking The Physiopathology Of Aortic Valve Stenosis In Vitro: Which Osteogenic Media On Human Valvular Interstitial Cells ? (2017) (0)
2FS05-4 Nuclear receptors controlling the metabolic syndrome and atherosclerosis (2003) (0)
Apolipoprotein a5-deficiency promotes cardiac glucose metabolism and protects against acute myocardial stresses (2014) (0)
EFFECTS OF PPAR γ LIGANDS ON ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE (2006) (0)
Liver X receptor activation decreases chylomicron assembly and improves post-prandial triglyceridemia via intestinal sr-bi downregulation (2014) (0)
Ketone Body Therapy Protects From Lipotoxicity and Acute Liver Failure Upon Ppar (cid:2) Deficiency (2015) (0)
PPARγ et athérome (2002) (0)
Body weight status and post-operative predictive significance of effective prosthetic orifice area after aortic valve replacement (2019) (0)
History of Discovery Fibrates, Glitazones, and Peroxisome Proliferator-Activated Receptors (2010) (0)
85 Transcriptional regulation of cardiac fatty acid metabolism: redundancy of the ligand-activated nuclear hormone receptors PPARa and PPARb/d (2003) (0)
3P-0834 Transcriptional regulation of the apolipoprotein A5 gene by insulin (2003) (0)
Superhumps and grazing eclipses in the dwarf nova BG Arietis (2011) (0)
Modification post-transcriptionelle et régulation de l’activité du récepteur nucléaire FXR par une protéine kinase (2012) (0)
Abstract 260: Identification of Micrornas Specifically Expressed in Isolated Cells of Human Abdominal Aortic Aneurysm (2015) (0)
Constitutive androstane receptor negatively regulates human apolipoprotein A-1 expression (2005) (0)
Computational analysis of carbohydrate metabolism (2010) (0)
PPAR&agr; Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages (2001) (0)
Nuclear bile acid signaling through the farnesoid X receptor (2014) (0)
Role of the nuclear receptor Rev-erb-alpha in the development of vascular calcification. (2017) (0)
PPARs regulate genes involved in cholesterol homeostasis in human monocyte/macrophages (2000) (0)
Astrophysics SDSS J 162520 . 29 + 120308 . 7 – a new SU Ursae Majoris star in the period gap (2011) (0)
Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism (2022) (0)
PPARS: Fatty acid-activated receptors controlling lipid metabolism and inflammation (2000) (0)
PPAR-ALPHA deficiency aggravates diabetes in ob/ob mice (2005) (0)
278-LB: Type 2 Diabetes (T2D) as a Risk Factor for NASH and Significant Liver Fibrosis (F>2) in an International Cohort of 2,363 Patients with Metabolic Steatosis (2019) (0)
VSX J074727.6+065050: a new WZ Sagittae star in Canis minor (2009) (0)
The HDAC inhibitor trichostatin A impairs pancreatic β-cell function through an epigenome-wide reprogramming (2022) (0)
3P-0818 GFT14, a novel compound with hypolipidemic and neuroprotective properties (2003) (0)
Rev-erb-α controls skeletal muscle calcium homeostasis through myoregulin repression: implications in Duchenne Muscular Dystrophy (2021) (0)
Screening strategy to generate cell specific recombination: a case report with the RIP-Cre mice (2015) (0)
Role of PPAR signalling in diabetic dyslipidemia (2010) (0)
VSX J003909.7+611233: a new slowly pulsating B (SPB) star in Cassiopeia? (2011) (0)
Dietary Sargassum fusiforme improves memory and reduces amyloid plaque load in an Alzheimer’s disease mouse model (2019) (0)
The conundrum of the functional relationship between transcription factors and chromatin. (2022) (0)
Small changes in the metabolism of bile acids by the gut microbiota are associated to NASH pathogenesis (2022) (0)
Generation and characterization of a humanized PPAR (cid:14) mouse model. (2019) (0)
Risperidone-induced metabolic dysfunction is attenuated by Curcuma longa extract administration in mice (2017) (0)
European Lipoprotein Club: Report of the 24th ELC Annual Conference, Tutzing, 10-13 September 2001. (2002) (0)
Precursor outbursts and superoutbursts in the SU UMa-type dwarf nova NN Camelopardalis (2010) (0)
European lipoprotein club: report of the 25th ELC annual conference. Tutzing, 9-12 September 2002. (2006) (0)
PPARα and IL-17A responses associated with the intestinal immune response against the protozoan parasite Giardia muris (2013) (0)
Indications and Clinical Use of Fibrates in Specific Lipoprotein Disorders Primary Hypertriglyceridemia (1998) (0)
GLP-1-mediated delivery of the PPAR𝛼/𝛾 dual-agonist Tesaglitazar improves obesity and glucose metabolism in mice (2021) (0)
W15-IS-001 PPARS as targets for anti-atherosclerotic therapies (2005) (0)
CA-141: Le facteur de transcription HNF4A est nécessaire pour réguler la protéine ANGPTL8 au cours de la progression d'une insulino-résistance chez l'homme (2016) (0)
Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα (2019) (0)
Cholesterol homeostasis is controlled by peroxisome proliferator-activated receptor alpha in human macrophages (2001) (0)
O89 Suppression of the tumour suppressor p16ink4a drives human macrophages towards a phenotype resembling adipose tissue macrophages (ATMs) (2010) (0)
miR-208 inhibits mitochondrial cardiomyocyte respiration in diabetic patients by inhibiting cytochrome C oxidase expression (2018) (0)
Developmental extinction of liver lipoprotein lipase mRNA expression is regulated by an NF-1 like site (1994) (0)
The intestinal FXR-mediated Fgf-115 pathway contributes to the diurnal control of hepatic bile acid synthesis and bile formation in chow fed mice but its contribution is overruled during bile acid feeding and bile acid sequestration (2009) (0)
Induction of Mdr2 expression as a component of the peroxisome proliferator-activated receptor alpha (PPAR alpha)-induced fasting response in the mouse. (2001) (0)
FXR and its ligands inhibit the function of platelets (2016) (0)
Results PPAR Mediates the Acute Antiinflammatory Action of Simvastatin In Vivo (1996) (0)
W15-P-004 PPAR-alpha deficiency aggravates diabetes in OB/OB mice (2005) (0)
INSERM U 325 Lille , France Recovery of Soluble , Active Recombinant Protein from Inclusion Bodies (1999) (0)
Contents, Vol. 40, 1993 (1993) (0)
p 16 deficiency promotes IL-4-induced polarization and inhibits INK 4 a proinflammatory signaling in macrophages (2013) (0)
2P-0529 A novel family of compounds with beneficial effects in mouse models of dyslipidemia and ischemic stroke (2003) (0)
The outburst of V713 Cephei in August 2009 (2010) (0)
CLINICAL — LIVER Ela ﬁ branor, an Agonist of the Peroxisome Proliferator L Activated Receptor L a and L d , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening (0)
THE FARNESOID X RECEPTOR INHIBITS THE TRANSCRIPTIONAL ACTIVITY OF THE CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN IN HUMAN HEPATOCYTES – R2 (2013) (0)
Abstract: P724 MACROPHAGES OF ADIPOSE TISSUE: POTENTIAL NEW TARGETS FOR NUCLEAR RECEPTOR LXR AGONISTS? (2009) (0)
PCr/ATP Ratios and Mitochondrial Function in The Heart. A Comparative Study in Humans. (2021) (0)
Metabolic and innate immune cues merge into a specific inflammatory response via unfolded protein response (UPR) (2020) (0)
Increases Hepatic ABCA 1 mRNA Expression and HDL-Cholesterol-Hydroxylase Deficiency in Mice on an APOE * 3-Leiden (2006) (0)
Comparison of the anti-inflammatory properties of selected DHA-derived oxylipins and insights into their mechanism of action (2016) (0)
Fatty acids as transcriptional regulators of the lipoprotein lipase and apo C-III genes: consequences for plasma triglyceride metabolism (1996) (0)
Method for identifying substances useful for treating inflammation embodying the element of receptor response ror the gene ikbalpha (2000) (0)
Preoperative white blood cells phenotype is associated with postoperative atrial fibrillation after cardiac surgery (2018) (0)
23-OR: The Effect of 14-Day Atorvastatin Treatment on Postprandial Glucose Metabolism in Healthy Males—A Link to Why Statin Therapy Increases the Risk of Type 2 Diabetes? (2019) (0)
Abstract: 513 THE PPAR FAMILY OF NUCLEAR RECEPTORS, THE METABOLIC SYNDROME, AND CVD (2009) (0)
[PPARgamma and atheroma]. (2002) (0)
SitesReveals Extensive Sharing of Binding in Mouse α Proliferator-Activated Receptor Retinoid X Receptor, and Peroxisome Genome-Wide Profiling of Liver X Receptor, (2012) (0)
The ubiquitin-like modifier FAT10 is upregulated during NASH and impairs PPAR-alpha activity (2022) (0)
Peroxisome Proliferator-Activated Receptor &agr; Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery Disease (2002) (0)
Peroxisome proliferator-activator receptor-α activator (PPAR-α) dose not inhibit the activation of human hepatic stellate cells by IL-1β (2003) (0)
Adipocyte-specific FXR-deficiency protects adipose tissue from oxidative stress and insulin resistance and improves glucose homeostasis (2023) (0)
CO-20: Caractérisation de la cardiomyopathie associée à la lipodystrophie congénitale généralisée de Berardinelli-Seip (2016) (0)
87 Clinical importance of new insights into the mechanism of activation of fibrates (1997) (0)
Gender specific improvement of synaptic function by activation of RXR nuclear receptor is mediated by PPAR alpha. (2019) (0)
Peroxisome proliferator activated receptors and energy metabolism (2005) (0)
Peroxisome Proliferator-Activated Receptors- (cid:1) and - (cid:2) , and cAMP-Mediated Pathways, Control Retinol-Binding Protein-4 Gene Expression in Brown Adipose Tissue (2012) (0)
SIRT1 activator SRT3025 provides atheroprotection in ApoE/ mice by increasing hepatic LDL receptor (2019) (0)
Induction of the plasma phospholipid transfer protein (PLTP) gene accounts for the HDL enlargement in mice treated with fenofibrate. Lack of HDL size redistribution in treated PLTP-deficient mice (2001) (0)
Paired biopsy analysis of human liver transcriptome before and 1 year after bariatric surgery identifies a restricted set of inflammation- and extracellular matrix-related genes as pivotal in NASH and fibrosis pathogenesis (2017) (0)
1334 CORRELATION OF HUMAN LIVER PPAR GENE EXPRESSION WITH HISTOLOGICAL SEVERITY OF NASH AND ASSOCIATED METABOLIC DERANGEMENTS: RATIONALE FOR TARGETED THERAPY (2013) (0)
Modulation of inflammatory M1-macrophages phenotype by valvular interstitial cells. (2022) (0)
Day-Time Declamping Is Associated with Better Outcomes in Kidney Transplantation: The Circarein Study (2021) (0)
PS1 - 2. Role of the tumour suppressor CDKN2A/p16INK4a in the development of perivascular adipose tissue (2013) (0)
0312: Characterization of human valvular interstitial cells isolated from normal and fibrocalcified aortic valves (2014) (0)
Le récepteur nucléaire FXR diminue la sécrétion de GLP-1 par les cellules entéroendocrines de type L en réponse aux métabolites du microbiote intestinal, les acides gras à chaîne courte (2017) (0)
The Digital Pathology Association's Annual Conference October 1-3 | Manchester Grand Hyatt | San Diego, CA (2017) (0)
Abstract: S2-27 REGULATION OF MACROPHAGE CHOLESTEROL TRANSPORT BY NUCLEAR RECEPTORS (2009) (0)
The PPARa-regulated dermatopontin is an important contributor to the liver fibrotic response in mouse models and has relevance to fibrosis progression in non-alcoholic fatty liver disease patients (2017) (0)
Nuclear receptor FXR controls sensitivity to the insulin (2006) (0)
Von Willebrand Factor As a Biological Sensor of Blood Flow in Percutaneous Cardiac Procedures (2014) (0)
[Inflammation and metabolic and vascular diseases: pharmacologic approaches]. (2006) (0)
[State of the art on the pathophysiology, diagnosis and treatment of non-alcoholic steatohepatitis (NASH)]. (2022) (0)
FXR-deficient mice are resistant to obesity induced by fad diets (2007) (0)
P263 STEATOSIS-INDEPENDENT PREVENTION OF LIVER FIBROSIS VIA THE TRANSREPRESSIVE ACTIVITY OF PPARa (2014) (0)
STATINS INCREASE EXPRESSION OF PLA2G7 IN MOUSE PERITONEAL MACROPHAGES (2008) (0)
The novel sirt1 activator srt3025 provides atheroprotection through increased hepatic low-density lipoprotein receptor expression (2013) (0)
Molecular mechanisms of action of fenofibrate (1998) (0)
Daytime variations in perioperative myocardial injury – Authors' reply (2018) (0)
Recovery of Soluble, Activ e Recombinant Protein from (1997) (0)
Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance (2020) (0)
O90 Régulation de la visfatin au sein des macrophages primaires par les récepteurs nucléaires PPAR (Peroxisome Proliferator-Activated Receptor) gamma et LXR (Liver X Receptors) (2010) (0)
We-W43:4 Proprotein convertase subtilisin/kexin type 9 is regulated by insulin, SREBP-1C and PPARalpha (2006) (0)
The U2-spliceosome and its interactors regulate the levels and activity of the LDL receptor in humans (2020) (0)
Le rôle de ses activateurs dans la régulation de l'expression des gènes impliqués dans le métabolisme des lipoprotéines, l'inflammation vasculaire et l'athérosclérose (2000) (0)
Pulsatility as modulator of acquired VWF defect in a pig model of continuous-flow ventricular assist device (2017) (0)
The Circadian Clock and Obesity. (2022) (0)
Abstract TP433: Free Leptin And Soluble Leptin Receptor: Novel Circulating Markers Of Carotid Plaque - Related Symptomatology And Potential Role In Plaque Stability (from The Opal-lille Carotid Endarterectomy Study) (2013) (0)
Golgi-associated protein sorting influences lipid droplet and lipoprotein formation (2015) (0)
4.P.367 Transcription factor genes controlling high density lipoprotein metabolism (1997) (0)
838 ALTERED EXPRESSION OF GLUCOSE AND LIPID REGULATORY GENES IN LIVER TISSUE RELATED TO THE SEVERITY OF NONALCOHOLIC FATTY LIVER DISEASE IN A LARGE PATIENT COHORT (2011) (0)
ATVB in Focus Nuclear Receptors in Metabolism and Cardiovascular Disease (2010) (0)
W40 FXR-DEFICIENCY IMPROVES GLUCOSE AND ENERGY HOMEOSTASIS IN GENETIC OBESITY (2010) (0)
The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids (2020) (0)
Response to Exercise and Hypertension Gene Regulates Left Ventricular Growth in α Activated Receptor − Peroxisome Proliferator (2002) (0)
0009 : Cardiac mitochondrial function is time-of-day dependent (2016) (0)
GENFIT : NEW PROOF OF EFFICACY OF GFT 505 IN NASH AND POSITIVE (2015) (0)
Circulating Monocyte Subsets and Transcatheter Aortic Valve Replacement (2022) (0)
Cell Metabolism, deadline February 7th, 2020 Title Microbiome modulation of host’s adaptive immunity through bile acid modification (2021) (0)
Induction of acyl-coenzyme a synthetase expression by fibrates and fatty acids is mediated through activation of the peroxisome proliferator activated receptor (1995) (0)
Macrophages in Obesity and Insulin Resistance (2014) (0)
PPAR&agr; Inhibits TGF-&bgr;–Induced &bgr;5 Integrin Transcription in Vascular Smooth Muscle Cells by Interacting With Smad4 (2002) (0)
Nuclear receptors in atherosclerosis (2004) (0)
0374 Leptin and its receptor in human calcific aortic valve: expression and functional implications (2014) (0)
A Single Dose of Oral Metformin Reduces the Post-Prandial Glucose Response Through a Transient Modulation of Apical Sodium-Glucose Co-Transporter (2019) (0)
Enterocyte Superoxide Dismutase 2 Deletion Drives Obesity (2021) (0)
The Identification of Novel Small Molecule Compounds with Potent Anti-Fibrotic Properties by Phenotypic Screening of Primary Human Stellate Cells (2016) (0)
The Nuclear Receptor Rev-erb-α Controls the Development of Vascular Calcification (2018) (0)
Impaired adaptive response to fasting in FXR-deficient mice (2005) (0)
O167 Pharmacological Sirt1 Activation In Apoe-/- Mice Provides Atheroprotection By Reducing Hepatic Pcsk9 Secretion And Enhancing Ldl-R Expression (2014) (0)
11. Nuclear receptors as targets to modulate HDL levels (1999) (0)
Fibrates and glitazones stimulate their inactivation through PPAR-dependent up-regulation of the drug metabolizing UGT1A9 enzyme (2003) (0)
The nuclear receptor FXR: a promising target for the metabolic syndrome? (2007) (0)
P729The functional relevance of bile acids in the improvement of HDL-mediated endothelial protection after bariatric surgery (2019) (0)
Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis (2022) (0)
Best Poster Award – Second Prize: Bile Acids as Novel Vascular Signalling Molecules and Therapeutic Target (2020) (0)
Development and implementation of a cell-based assay to discover agonists of the nuclear receptor REVERB α (2018) (0)
P715Deletion of fibroblast activation protein decreases experimental atherosclerotic plaque formation and vulnerability (2019) (0)
Abstract 1719: Tissue Factor Pathway Inhibitor-2 Gene Hypermethylation is Associated with Low Expression in Carotid Atherosclerotic Plaques (2006) (0)
The nuclear receptor FXR regulates adipocyte differentiation and function by interfering with the Wnt/beta-catenin and by inducing path fignalisation PPAR. (2010) (0)
Processes of identifying compounds that modulate the reverse transport of cholesterol (2001) (0)
Abstract: 72 EFFECT OF A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR) BETA/DELTA AGONIST ON LIPOPROTEIN KINETICS IN THE METABOLIC SYNDROME (2009) (0)
Regulation of liver lipoprotein lipase gene expression (1995) (0)
High level expression of PPARγ in differentiated colon epithelium (1998) (0)
VizieR Online Data Catalog: SDSS J162520.29+120308.7 (Olech+, 2011) (2012) (0)
839 SERUM APOLIPOPROTEIN CIII LEVELS DECLINE AFTER WEIGHT LOSS INDUCED IMPROVEMENT IN HEPATIC STEATOSIS (2011) (0)
1.P.199 The underlying mechanism of the hypolipidemic effect of 3-thia fatty acids (1997) (0)
Omentin-1, epicardial fat and coronary artery disease. (2016) (0)
Abstract 12263: The Role of Glucagon-Like Peptide-1 in the Immediate Improvement of Endothelial-Protective HDL Functions After Roux-en-Y Gastric Bypass in Obese Patients (2014) (0)
Peroxisome proliferator-activated receptors in inﬂammation control (2001) (0)
LIVER X RECEPTORS (LXRS): TRANSCRIPTIONAL REGULATORS OF MACROPHAGE CHOLESTEROL METABOLISM (2006) (0)
Coronary Atherosclerosis and Risk of Coronary Artery Disease Gene Variants Influence Progression of α Peroxisome Proliferator-Activated Receptor (2002) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Bart Staels?

Bart Staels is affiliated with the following schools:

Bart Staels's Academic­Influence.com Rankings

Why Is Bart Staels Influential?

Bart Staels's Published Works

Published Works

What Schools Are Affiliated With Bart Staels?

Bart Staels's AcademicInfluence.com Rankings